Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

As illustrated in Figure 2B, calcitriol treatment significantly increased the ipsilateral PWT in SNI rats at an effective dose of 1 or 2 μg compared with the SNI + Vehicle group.

Source: The Analgesic Effect of VitD3 in SNI Rats. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Animal research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This study explores the therapeutical role and potential mechanism of VitD3 in spared nerve injury (SNI)‐induced neuropathic pain rat model.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Vitamin D3 Attenuates Neuropathic Pain via Suppression of Mitochondria‐Associated Ferroptosis by Inhibiting PKCα/NOX4 Signaling Pathway

Study design awaiting verification · CNS Neuroscience & Therapeutics · 2024

Original publication title

Vitamin D3 Attenuates Neuropathic Pain via Suppression of Mitochondria‐Associated Ferroptosis by Inhibiting PKCα/NOX4 Signaling Pathway

Wencui Zhang; Shangchen Yu; Bo Jiao; Caixia Zhang; Kaiwen Zhang; Baowen Liu; Xianwei Zhang

© 2024 The Author(s). CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Overall, our study for the first time concludes that VitD3 ameliorates neuropathic pain by preventing the loss of spinal GABAergic interneurons, which is attributed to the activation of VDR and subsequent inhibition of mitochondria‐associated ferroptosis mediated by PKCα/NOX4 signaling pathway. These findings provide a rationale based on the mechanism for the translation of VitD3 from bench to bedside as an adjunctive analgesic for the management of neuropathic pain.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Neuropathic pain remains a significant unmet medical challenge due to its elusive mechanisms. Recent clinical observations suggest that vitamin D (VitD) holds promise in pain relief, yet its precise mechanism of action is still unclear. This study explores the therapeutical role and potential mechanism of VitD3 in spared nerve injury (SNI)‐induced neuropathic pain rat model.

Source: Aims

Study methods

What methods does the paper describe?

2.1

Animals

Adult male Sprague: Dawley rats (weighing 200 to 240 g, supplied from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) were used in this study. Rats were randomly grouped and housed in an environment with a temperature (23 ± 2°C), relative humidity (45%: 65%), lighting (12‐h light/dark cycle). All rats must acclimate to standard conditions for at least 7 days upon arrival, with free access to food and water. Animal procedures were approved by the Ethics Committee of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology (Number: TJH‐202306019) and in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and ARRIVE Guidelines for Reporting Animal Research.

All experiments were completed in the Experimental Medicine Research Center of Tongji hospital.

2.2

Chemicals and Reagents

VitD3 (Calcitriol, cat: HY‐10002, purity > 95%) was dissolved in a solution containing 10% DMSO and 90% corn oil. RSL3 (cat: HY‐100218A), an activator of ferroptosis through inactivate GPX4, was dissolved in 10% DMSO and 90% corn oil. The PKCα inhibitor bisindolylmaleimide I (BIM‐1, cat: HY‐13867) was dissolved in 10% DMSO and 40% PEG300 and 5% Tween‐80 in sterile saline. The PKCα agonist phorbol 12‐myristate 13‐acetate (PMA, cat: HY‐18739) was dissolved in 10% DMSO and 40% PEG300 and 5% Tween‐80 in sterile saline.

The vehicles were formulated on the basis of the corresponding solvent medium. All the chemicals employed in the present study were purchased from Med Chem Express (Shanghai, China). Iron Assay Kit (cat: A039‐2‐1), malondialdehyde (MDA) Assay Kit (cat: A003‐1‐1), ROS Assay Kit (cat: E004‐1‐1), Superoxide Dismutase (SOD) Assay Kit (cat: A001‐1‐1), GSH Assay Kit (cat: A006‐2‐1), and ATP Assay Kit (cat: A095‐1‐1) were purchased from Jiancheng Biology (Nanjing, China). Perl's staining Kit was purchased from Servicebio (Wuhan, China). The antibodies used in the molecular studies were showed in Table 1.

TABLE 1

Primary and secondary antibodies for western blot and immunofluorescence.

AntibodyProviderHostCatalog numberDilution for WBDilution for IF
VDRProteintechMouse67,192‐1‐Ig1:2000
AbclonalRabbitA21941:50
p‐PKCαAffinityRabbitAF83961:10001:50
PKCαAbclonalRabbitA111071:1000
NOX4ProteintechRabbit14,347‐1‐AP1:20001:50
SLC7A11AbclonalRabbitA24131:2000
GPX4AbclonalRabbitA112431:2000
GAD65Zen‐bioMouse201,3081:1000
NDUFB8AbclonalRabbitA197321:1000
SDHBAbclonalRabbitA18091:1000
UQCRC2AbclonalRabbitA43661:2000
MTCO1AbclonalRabbitA178891:1000
ATP5A1AbclonalRabbitA112171:2000
β‐ActinAbclonalRabbitAC0381:10000
IBA‐1Gene TexMouseGTX6324261:200
NeuNAbcamMouseAb1042241:200
GFAPCSTMouse#36701:200
Anti‐rabbit IgG HRPAbclonalGoatAS0141:5000
Anti‐mouse IgG HRPAbclonalGoatAS0031:5000
Coralite488‐conjugated anti‐mouse IgGProteintechGoatSA00013‐51:200
Coralite594‐conjugated anti‐rabbit IgGProteintechMouseSA00013‐81:200

Abbreviations: ATP5A1 (also term as ATP5F1A), ATP synthase F1 subunit alpha; GAD65, glutamic acid decarboxylase 65; GFAP, glial fibrillary acidic protein; GPX4, glutathione peroxidase 4; HRP, horseradish peroxidase; IBA1, ionized calcium‐binding adapter molecule 1; MTCO1, mitochondrially encoded cytochrome c oxidase I; NDUFB8, NADH: Ubiquinone Oxidoreductase Subunit B8; NeuN, neuronal nuclei; NOX4, NADPH oxidase 4; PKCα, protein kinase C alpha; SDHB, succinate dehydrogenase complex iron sulfur subunit B; SLC7A11, subunit solute carrier family 7 member 11; UQCRC2, ubiquinol‐cytochrome c reductase core protein 2; VDR, vitamin D receptor.

2.3

Experimental Design

In the present study, all rats were randomly allocated to different groups using a computer‐generated random number table. All the experimental procedures and analyses were blindly performed by researchers unaware of the group assignments. Five main experiments were designed to investigate the analgesic mechanism of VitD3 in neuropathic pain.

2.3.1
Experiment 1

Rats were randomly assigned to the sham or SNI group. Paw withdrawal thresholds (PWTs) were measured on Days 3, 7, and 14 after surgery. Then, the L4: L6 spinal cords from the sham group and the SNI group at 3, 7, and 14 days after surgery were collected for western blot and Kit detection. We chose rats 7 days after SNI for double immunofluorescence colocalization and Perl's staining.

2.3.2
Experiment 2

To verify whether a single dose of calcitriol could attenuate mechanical allodynia, rats were randomly divided into four groups, respectively: SNI + Vehicle; SNI + 0.5 μg calcitriol; SNI + 1 μg calcitriol; SNI + 2 μg calcitriol. Vehicle and different doses of calcitriol were intrathecally (i.t.) administrated on 7 days after surgery. To assess the effect of continuous calcitriol injection on mechanical allodynia in SNI, rats were randomly divided into four groups: Sham + Vehicle; Sham + calcitriol; SNI + Vehicle; SNI + calcitriol.

Calcitriol (1 μg, i.t.) was administrated once daily for 5 consecutive days, starting on the 7th day after surgery.

2.3.3
Experiment 3

To investigate whether the ferroptosis agonist RSL3 could blocked the protective effect of calcitriol, rats were randomly divided into 2 groups:SNI + calcitriol and SNI + calcitriol + RSL3. Calcitriol alone or co‐administrated with RSL3 (5 μg) was intrathecally injected once daily for 5 consecutive days, starting on the 7th after the surgery. The dose of RSL3 was chosen on the basis of unpublished data from our laboratory.

2.3.4
Experiment 4

To investigate whether pharmacological inhibition of PKCα/NOX4 signaling pathway could attenuate mechanical allodynia, rats were randomly divided into four groups: Sham + Vehicle; Sham + BIM‐1; SNI + Vehicle; SNI + BIM‐1. BIM‐1 (100 μM) was intrathecally administrated into corresponding rats according to a previous study [28], from 7 to 11 days after surgery.

2.3.5
Experiment 5

To study the role of PKCα/NOX4 signaling pathway in the analgesic effect of calcitriol, naïve rats were randomly divided into three groups: Vehicle, Vehicle + PMA, Vehicle + PMA + Calcitriol. A single dose of PMA (2 μg) or a combination of calcitriol were intrathecally injected into naïve rats. The dose of PMA was chosen on the basis of previous studies [29].

2.4

Neuropathic Pain Model

The SNI rat model of neuropathic pain was induced as previously described [30]. Briefly, the rats were anesthetized with 2.5% isoflurane and were placed in a left decubitus position; an incision of approximately 1 cm was made at the mid‐thigh level, the left sciatic nerve and its three branches (the common peroneal, tibial, sural nerves) were carefully exposed and separated. Then, the common peroneal and tibial nerves were ligated together and transected distally, leaving the sural nerve intact.

The skin incision was sutured with 3.0 silk and disinfected. The sham‐operated animals underwent exactly the same procedure without nerve injury.

2.5

Behavioral Testing

The mechanical allodynia was evaluated by measuring the hind PWT in response to von Frey filament stimuli, as previously described [31]. In brief, rats were individually positioned in test cages with a mesh floor and habituated for 30 min before von Frey testing. The von Frey filaments ranging from 1.4 to 15 g were vertically applied in ascending order on the mid‐plantar of the hind paw, bending the filament for 3 to 5 s. A positive response was defined as quick paw withdrawal, licking, or shaking.

The lowest force required to elicit a positive response was recorded as PWTs. All behavioral tests were performed between 9:00 a.m. and 6:00 p.m. by an investigator blinded to the experimental design.

2.6

Intrathecal Catheterization and Drug Administration

For intrathecal drug administration, the intrathecal catheterization was completed at least 5 days prior to sham or SNI surgery as previously reported [32]. Rats were deeply anesthetized with isoflurane (2.5%) and implanted with PE‐10 catheters (inner diameter 0.3 mm, outer diameter 0.6 mm) into the intrathecal space at the L4‐L6 level. The correct position of the catheter was confirmed by the tail‐flick response immediately following the insertion of the catheter. After surgery, 2% lidocaine (10 μL) was delivered through the intrathecal catheter, and both hind limbs of the rats showed temporary paralysis, indicating the success of catheterization.

Animals with visible motor dysfunction were excluded from the experiment. In this study, we aimed to investigate a purely spinal mechanism. All drugs were intrathecally injected at 10 μL, followed by 10 μL saline for flushing. Detailed experimental plans for animal assignment and medication are outlined in the respective timeline diagram.

2.7

Western Blot

Under deep anesthetized, the L4‐L6 spinal cord was quickly removed and homogenized in ice‐cold RIPA lysis‐buffer containing a cocktail of protease and phosphatase inhibitors. The lysates were then centrifuged at 12,000 rpm at 4°C for 15 min, and the protein concentration of supernatants was measured using BCA method. Equal amounts of protein samples (40 μg) were separated by 10% sodium dodecyl sulfate: polyacrylamide gels electrophoresis (SDS‐PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). After blocking with 5% non‐fat milk for 2 h at RT, the membranes were incubated with the primary antibodies (Table 1) overnight at 4°C.

Following washes in TBST three times, the blots were incubated with an HRP‐conjugated secondary antibody for 2 h at RT and visualized with Super Lumia ECL Plus HRP Substrate Kit (Abbkine). The bolts were scanned and quantified using the ChemiDoc XRS System (Bio‐Rad, CA, USA). The intensity of bands was normalized to the β‐Actin and expressed as fold changes over the control group. For successive antibody incubations, the primary and secondary antibodies were removed using a commercial stripping solution (Epizyme Biotech, Shanghai, China), and the membranes were re‐immunoblotted for additional molecules.

2.8

Paraffin Section Preparation

After deep anesthesia with 2.5% isoflurane, rats were intracardially perfused with ice‐cold 0.1 M PBS followed by 4% paraformaldehyde in PBS. Subsequently, the L4‐L6 spinal cord segments were harvested, fixed in 4% PFA at room temperature, dehydrated, and embedded in paraffin. Four‐micrometer thick paraffin sections were used for immunofluorescence and Perl's staining.

2.9

Double‐Labeling Immunofluorescence

After deparaffinization and hydration, the sections were microwaved in 0.01 M sodium citrate (PH 6.0) for antigen retrieval. The sections were penetrated with 0.3% TritonX‐100 for 15 min and blocked with 5% donkey serum for 1 h at RT. Then, the sections were incubated with the primary antibodies (Table 1) overnight at 4°C. After washing with PBS three times, the sections were incubated with the secondary antibodies (Table 1) for 2 h at RT. The nuclei were stained with DAPI for 5 min, and images were captured using a fluorescence microscope (BX51, OLYMPUS, Japan).

2.10

Perl's Staining and Iron Content Detection

Iron deposition was measured in spinal cord by Perl's staining. Perl's staining working solution was added to the deparaffinized and hydrated sections. Then, hemosiderin or ferric iron staining was observed under the microscope. The concentration of Fe2+ in the spinal cord expressed as nmol/g protein was measured with a kit assay according to the manufacturer's protocols.

2.11

ROS, MDA, GSH, and SOD Measurements

The contents of ROS, MAD, GSH, and SOD in spinal cord tissues were detected using commercial assay kits according to the manufacturer's protocol. The content of MDA, GSH, and SOD was expressed as nmol/g protein, μmol/g protein, and U/g protein, respectively.

2.12

Measurement of ATP Levels

The ATP levels of the spinal cord were calculated with an assay kit following the manufacturer's operation manual. The concentration of ATP was expressed in the form of μmol/g protein.

2.13

Transmission Electron Microscope

Rats were deeply anesthetized and transcardially perfused with 0.1 M PBS followed by 4% ice‐cold PFA, the spinal cord was dissected out and sliced into 1 mm2 sections. The sections were fixed in 2% glutaraldehyde, post‐fixed in 1% aqueous osmium tetraoxide for 2 h at RT, dehydrated in gradual ethanol, and embedded in epoxy resin. Ultrathin slides were obtained using ultra‐micro‐tome (Leica, Germany) and double‐stained with uranyl acetate and lead citrate. Images were captured by transmission electron microscopy (Thermo, USA).

2.14

Statistical Analysis

All experimental data are presented as mean ± SD and analyzed using GraphPad Prism version 6 (Graph Pad Software, San Diego, CA, USA). All data underwent normality testing using either the Shapiro: Wilk test. Differences in behavioral scores among groups were analyzed by two‐way repeated measures analysis of variance (ANOVA), followed by Bonferroni's post hoc test. In other trails, Student's t‐tests were used for comparisons between two groups, and one‐way ANOVA followed by the Bonferroni test was used for comparisons between multiple groups.

For all statistical analyses, p < 0.05 was interpreted as statistically significant.

Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods Source: Materials and Methods

VitD3 Attenuates Ferroptosis and GABAergic Interneuron Loss in the Spinal Cord of SNI Rats

Results: VitD3 Attenuates Ferroptosis and GABAergic Interneuron Loss in the Spinal Cord of SNI Rats

To investigate whether VitD3 could inhibit the enhanced ferroptosis induced by SNI, we assessed the changes in ferroptosis‐related indicators in the spinal cord. As illustrated in Figure 3A, treatment with calcitriol significantly alleviated the increased level of Fe2+, ROS, and MDA in the spinal cord compared with the SNI + Vehicle group. Meanwhile, the suppressed activity of GSH and SOD was reversed by calcitriol treatment. Furthermore, western blot analysis revealed that calcitriol treatment significantly hindered the SNI‐induced downregulation of GPX4 and SLC7A11 (Figure 3B,C).

These data support the resistant role of VitD3 in ferroptosis under neuropathic pain conditions.

FIGURE 3

VitD3 attenuated ferroptosis and GABAergic interneuron loss in the spinal cord of SNI rats. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord were measured with corresponding kits (n = 5 to 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001 versus Sham + Vehicle group, # p < 0.05, ## p < 0.01 versus SNI + Vehicle group. (B, C) Representative blots and quantification of SLC7A11 and GPX4 in the spinal cord of different groups were presented (n = 6 per group). ****p < 0.0001 versus the Sham + Vehicle group, ### p < 0.001, #### p < 0.0001 versus the SNI + Vehicle group. (D, E) Representative blots and quantification of GAD65 in the spinal cord of different groups were presented (n = 6 per group). ****p < 0.0001 versus the Sham + Vehicle group, #### p < 0.0001 versus the SNI + Vehicle group. (F) The timeline of experimental procedures. (G) Rats were intrathecally administered with calcitriol (1 μg) alone or co‐application with RSL3 (5 μg) once daily from Day 7 to Day 11 following SNI.

Mechanical allodynia was conducted at 2 h after daily treatment, **p < 0.01, ***p < 0.001 versus SNI + Calcitriol group, n = 6 per group. (H, I) Representative western blot bands and quantification of GAD65 and GPX4 in the spinal cord of SNI + Calcitriol and SNI + Calcitriol+RSL3 group were presented. ****p < 0.0001 < 0.0001 versus SNI + Calcitriol group, n = 6 per group.

Figure image at the original source: open the original paper. This file is not included in this text import.

Considering the neuroprotective effect of VitD3 in neurodegenerative disease [22], we investigated whether VitD3 could reduce SNI‐induced neuronal injury, particularly the GABAergic interneurons in the spinal cord. Glutamic acid decarboxylase 65 (GAD65) is a GABA‐synthesizing enzyme that can be used to indicate the number and functional changes of GABA interneurons [35]. Consequently, we observed a statistically significant decrease in the protein levels of GAD65 in the spinal cord following SNI, and treatment with calcitriol markedly enhanced the expression of GAD65 (Figure 3D,E).

To deeply explore whether the protective effect on GABA neurons was attributed to the inhibition of ferroptosis by calcitriol, the ferroptosis inducer RSL3 (5 μg) combined with calcitriol was intrathecally injected into SNI rats and then measured the pain behavior. The timeline of this test is displayed in Figure 3F. As shown in Figure 3G, the behavioral test showed that the RSL3 treatment partially abolished the antinociceptive effect of calcitriol. Moreover, western blot results revealed that administration of RSL3 significantly hindered the upregulation of GAD65 and GPX4 induced by calcitriol treatment (Figure 3H,I).

These data hint that VitD3 protects the spinal GABAergic interneuron against ferroptosis, thereby attenuating neuropathic pain.

Source: VitD3 Attenuates Ferroptosis and GABAergic Interneuron Loss in the Spinal Cord of SNI Rats Source: VitD3 Attenuates Ferroptosis and GABAergic Interneuron Loss in the Spinal Cord of SNI Rats Source: VitD3 Attenuates Ferroptosis and GABAergic Interneuron Loss in the Spinal Cord of SNI Rats

PKCα/NOX4 Signaling Pathway Is Involved in the Development of SNI‐Induced Neuropathic Pain

Results: PKCα/NOX4 Signaling Pathway Is Involved in the Development of SNI‐Induced Neuropathic Pain

It was previously reported that PKCα contributed to pain hypersensitivity in chronic inflammatory pain [38]. Moreover, NOX4 is a downstream effector of PKCα that generates ROS and is also involved in pain processing [39]. Accordingly, we examined the levels of p‐PKCα, PKCα, and NOX4 in the spinal cord by western blot. As illustrated in Figure 5A,B, compared with the sham control, the protein expression of p‐PKCα, PKCα, and NOX4 consistently increased in the spinal cord from Day 3 to Day 14, peaking on Day 7.

Additionally, double immunostaining showed that both p‐PKCα and NOX4 were predominately colocalized with neurons in the spinal dorsal horn, but rarely with astrocytes or microglia (Figure 5C,D). These results suggest that the PKCα/NOX4 signaling pathway may function in spinal dorsal neurons in pain processing.

FIGURE 5

PKCα/NOX4 signaling pathway was involved in the development of SNI‐induced neuropathic pain. (A, B) Time course of p‐PKCα, PKCα, and NOX4 in the spinal cord of after SNI (n = 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus sham group. (C, D) Double immunofluorescence of p‐PKCα and NOX4 with GFAP, IBA1, and NeuN in the spinal dorsal horn of SNI rats (n = 4 per group).

The white boxes indicated typical co‐staining cells. Scale bar: 100 and 50 μm. (E) The time schedule of the present experiment. (F) BIM‐1 (100 μM, i.t.) was given once daily from Day 7 to Day 11 following SNI. Mechanical allodynia was performed at 1.5 h after daily treatment. ***p < 0.001, ****p < 0.0001 versus Sham + Vehicle group, #### p < 0.000 versus SNI + Vehicle group. (G, H) Representative western blot bands and quantification of J p‐PKCα, PKCα, and NOX4 in the spinal cord among groups, **p < 0.01, ***p < 0.001 versus the sham group, ### p < 0.001, #### p < 0.0001 versus the SNI + Vehicle group, n = 6 in each group.

Figure image at the original source: open the original paper. This file is not included in this text import.

To confirm the role of the PKCα/NOX4 signaling pathway in SNI‐induced neuropathic pain, we applied a pharmacological approach using the broad‐range PKCα inhibitor BIM‐1. The timeline of this test is depicted in Figure 5E. BIM‐1(100 μM) was intrathecally injected for 5 consecutive days starting from Day 7 after SNI, and the behavioral test was conducted before and 1.5 h after BIM‐1 injection. As illustrated in Figure 5F, the behavioral test showed that the PWT was significantly increased in BIM‐1‐treated rats compared with the vehicle‐treated rats.

Importantly, administration of BIM‐1 markedly reduced the protein expression of p‐PKCα, PKCα, and NOX4 in the spinal cord (Figure 5G,H). These results suggest that the spinal PKCα/NOX4 signaling pathway plays a functional role in neuropathic pain.

Source: PKCα/NOX4 Signaling Pathway Is Involved in the Development of SNI‐Induced Neuropathic Pain Source: PKCα/NOX4 Signaling Pathway Is Involved in the Development of SNI‐Induced Neuropathic Pain Source: PKCα/NOX4 Signaling Pathway Is Involved in the Development of SNI‐Induced Neuropathic Pain

Pharmacological Inhibition of PKCα/NOX4 Signaling Pathway Suppressed Ferroptosis and Mitochondrial Dysfunction

Results: Pharmacological Inhibition of PKCα/NOX4 Signaling Pathway Suppressed Ferroptosis and Mitochondrial Dysfunction

Next, to test whether the PKCα/NOX4 signaling pathway contributed to SNI‐induced ferroptosis and mitochondrial dysfunction, we assessed the changes in ferroptosis‐related indexes in the spinal cord after intrathecal injection with BIM‐1. As shown in Figure 6A, compared with the vehicle‐treated group, the level of Fe2+, ROS, and MDA were significantly decreased by BIM‐1 treatment, while the activity of GSH and SOD were increased. In response to BIM‐1 treatment, higher levels of GPX4 and SLC7A11 in the spinal cord were observed in SNI rats (Figure 6B,C).

Simultaneously, BIM‐1 treatment significantly attenuated SNI‐caused decline in ATP contents (Figure 6D). As expected, western blot results showed that BIM‐1 administration significantly increased the levels of ETC Complex III, IV, and V in the spinal cord of SNI rats, as compared to the vehicle‐treated group (Figure 6E,F). The influence of BIM‐1 on mitochondrial morphology was also evaluated, and the mitochondrial morphological injury in spinal neurons caused by SNI was alleviated by BIM‐1 treatment (Figure 6G). These results suggest that SNI‐triggered ferroptosis and mitochondrial dysfunction in the spinal cord probably in a PKCα/NOX4 signaling pathway‐dependent manner.

FIGURE 6

Pharmacological inhibition of PKCα/NOX4 signaling pathway suppressed ferroptosis and mitochondrial dysfunction. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord of SNI + Vehicle and SNI + BIM‐1 groups were measured (n = 5 to 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001 versus SNI + Vehicle group. (B, C) Representative blots and quantification of SLC7A11 and GPX4 in the spinal cord of different groups were presented (n = 5 to 6 per group). ***p < 0.001, ****p < 0.0001 versus sham group, ## p < 0.01, ### p < 0.00 versus SNI + Vehicle group. (D) The levels of ATP in spinal cord of SNI + Vehicle and SNI + BIM‐1 groups were measured (n = 6 per group). *p < 0.05 versus SNI + Vehicle group. (E, F) Representative western blot bands of mitochondrial ETC Complex III‐V (UQCRC2, MTCO1, and ATP5F1A) in the spinal cord of different groups were presented.

Quantitative analysis of scanning densitometry was performed. *p < 0.05, **p < 0.01 versus Sham + Vehicle group, # p < 0.05, ## p < 0.01 versus SNI + Vehicle group, n = 5 in each group. (G) Representative electron morphological changes of the mitochondrial in the spinal cord of SNI + Vehicle and SNI + BIM‐1 groups (n = 3 per group). The labeled yellow boxes highlight the mitochondrial ultrastructure. scale bar: 1 μm and 500 nm.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Pharmacological Inhibition of PKCα/NOX4 Signaling Pathway Suppressed Ferroptosis and Mitochondrial Dysfunction Source: Pharmacological Inhibition of PKCα/NOX4 Signaling Pathway Suppressed Ferroptosis and Mitochondrial Dysfunction

VitD3 Alleviates Pain Hypersensitivity via Inhibiting PKCα/NOX4 Signaling Pathway

Results: VitD3 Alleviates Pain Hypersensitivity via Inhibiting PKCα/NOX4 Signaling Pathway

The molecular basis for the analgesic effect of VitD3 remains to be elucidated. Based on our above findings, we further explored the role of the PKCα/NOX4 signaling pathway in VitD3‐mediated antinociception. As a result, western blot results displayed that calcitriol treatment significantly reduced the protein levels of p‐PKCα, PKCα, and NOX4 in the spinal cord, as compared to the vehicle‐treated SNI group (Figure 7A,B). To further verify the potential relationship between the PKCα/NOX4 signaling pathway and VitD3 in nociception, we treated naïve rats with the PKCα activator PMA alone or in combination with calcitriol and analyzed the changes in pain behavior.

The schedule for the drug delivery and testing is shown in Figure 7C. PMA (2.5 μg) and calcitriol were intrathecally given in a single dose, and the PWT was measured before the injection and 0.5 to 12 h after the injection. As illustrated in Figure 7D, compared with the vehicle group, rats that received a single dose of PMA exhibited a significantly decreased PWT from 1 h after injection, and lasted at least to 12 h. Moreover, calcitriol treatment attenuated the mechanical allodynia induced by PMA administration.

The analgesic effect peaked at 2 h and lasted only for 2 h. Accordingly, the spinal segments were collected at 2 h after drug administration. As expected, western blot results showed that the spinal expression of p‐PKCα/PKCα and NOX4 was significantly enhanced in response to PMA injection, which were markedly inhibited by calcitriol treatment (Figure 7E,F). Taken together, these results highlight the involvement of PKCα/NOX4 signaling pathway in the antinociceptive effect of VitD3.

FIGURE 7

VitD3 alleviated pain hypersensitivity via inhibiting PKCα/NOX4 signaling pathway. (A, B) Representative western blot bands and quantification of p‐PKCα, PKCα, and NOX4 in the spinal cords of animals from different groups were presented. **p < 0.01 versus Sham + Vehicle group, ## p < 0.01, ### p < 0.001 versus SNI + Vehicle group, n = 6 in each group. (C) Time schedule of the experiment. (D) Naïve rats were intrathecally injected with a single dose of PMA (2.5 μg) alone or in combination with calcitriol (1 μg).

Mechanical allodynia was measured before injection and 0.5, 1, 2, 4, 6, and 12 h after injection. ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats, n = 6 in each group. (E, F) Representative western blot bands and quantification of p‐PKCα and NOX4 in the spinal cords of animals from different groups were presented. The phosphorylation levels of PKCα were normalized to the total protein levels. **p < 0.01, ***p < 0.001 compared with Vehicle‐treated rats, ## p < 0.01 compared with PMA‐treated rats, n = 4 to 6 in each group.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: VitD3 Alleviates Pain Hypersensitivity via Inhibiting PKCα/NOX4 Signaling Pathway Source: VitD3 Alleviates Pain Hypersensitivity via Inhibiting PKCα/NOX4 Signaling Pathway

VitD3 Preserves Spinal GABAergic Interneurons via Suppression of PKCα/NOX4 Signaling Pathway‐Mediated Ferroptosis and Mitochondrial Dysfunction

Results: VitD3 Preserves Spinal GABAergic Interneurons via Suppression of PKCα/NOX4 Signaling Pathway‐Mediated Ferroptosis and Mitochondrial Dysfunction

To ascertain whether VitD3 suppressed pain behaviors induced by PKCα/NOX4 pathway activation in naïve rats involves a similar mechanism in SNI rats, we further examined the expression of ferroptosis markers and GAD65 in the spinal cord. Surprisingly, PMA administration induced a dramatic elevation in Fe2+, ROS, and MDA, and a decline in GSH and SOD in the spinal cord, all of which were reversed by calcitriol treatment (Figure 8A). Additionally, calcitriol treatment significantly alleviated PMA‐induced downregulation of spinal SLC7A11 and GPX4, as well as GAD65 (Figure 8B: E).

Furthermore, the effects of VitD3 on PKCα/NOX4 pathway‐mediated mitochondrial function were also explored. As shown in Figure 8F, the ATP content was significantly decreased after PMA administration compared with the vehicle group. Intriguingly, calcitriol treatment significantly restored PMA‐induced downregulation of ATP. Simultaneously, the protein levels of ETC Complex III, IV, and V were obviously decreased in the spinal cord of PMA‐treated rats, which were dramatically alleviated by calcitriol treatment (Figure 8G,H). Furthermore, TEM results showed swollen mitochondria with reduction in cristae and rupture of the outer membrane in spinal cord neurons after PMA administration (Figure 8I).

However, calcitriol treatment attenuated these mitochondrial damages. These findings suggest that the protective effect of VitD3 on spinal GABAergic interneurons through the suppression of PKCα/NOX4 signaling pathway‐mediated ferroptosis and mitochondrial dysfunction.

FIGURE 8

VitD3 preserved spinal GABAergic interneurons via suppression of PKCα/NOX4 signaling pathway‐mediated ferroptosis and mitochondrial dysfunction. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord in different groups were assessed (n = 4 to 6 per group). **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, # p < 0.05, ## p < 0.01, ### p < 0.001 compared with PMA‐treated rats. (B, C) Representative western blot bands and quantification of SLC7A11 and GPX4 in the spinal cords of different groups were presented (n = 6 per group). ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats. (D, E) Representative western blot bands and quantification of GAD65 in the spinal cords of different groups were presented (n = 6 per group). ****p < 0.0001 compared with Vehicle‐treated rats, #### p < 0.0001 compared with PMA‐treated rats. (F) The levels of ATP in spinal cord were measured (n = 5 per group). ***p < 0.001 compared with Vehicle‐treated rats, # p < 0.05 compared with PMA‐treated rats. (G, H) Representative western blot bands of mitochondrial ETC Complex III‐V (UQCRC2, MTCO1, and ATP5F1A) in the spinal cord of different groups were presented. ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats, n = 5 to 6 in each group. (I) Representative morphological changes in the mitochondrial in the spinal cord (n = 3 per group).

The labeled yellow boxes highlight the mitochondrial ultrastructure. scale bar: 1 μm and 500 nm.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: VitD3 Preserves Spinal GABAergic Interneurons via Suppression of PKCα/NOX4 Signaling Pathway‐Mediated Ferroptosis and Mitochondrial Dysfunction Source: VitD3 Preserves Spinal GABAergic Interneurons via Suppression of PKCα/NOX4 Signaling Pathway‐Mediated Ferroptosis and Mitochondrial Dysfunction

Discussion

Albeit the understanding of the mechanism underlying neuropathic pain has been deepened over the past decades, the first‐line pharmaceutical therapy for neuropathic pain often has limited efficacy and non‐negligible side effects [3]. Interest in Vitamin D as an alternative therapeutic approach for neuropathic pain has recently increased dramatically [40, 41]. However, the underlying mechanism of the action remains unclear. In the present study, we showed that intrathecal administration of VitD3 alleviated mechanical allodynia by preventing the loss of GABAergic interneurons in the spinal cord.

This effect may be related, at least in part, to the inhibition of mitochondrial‐associated ferroptosis mediated by the PKCα/NOX4 signaling pathway, in a VDR‐activated manner. These results provided new theoretical evidence and a novel perspective regarding the utilization of VitD3 for treating neuropathic pain.

Ferroptosis is a unique modality of regulated cell death that distinct from apoptosis and necroptosis, characterized by lipid peroxidation initiated by iron overload and ROS generation [9]. Iron overload facilitates excessive ROS production via the Fenton reaction, which interacts with polyunsaturated fatty acids (PUFAs) of lipid membranes and induce lipid peroxidation, and eventually leads to ferroptosis‐like cell death [42]. Additionally, inactivation of GPX4 by GSH depletion promotes ROS accumulation from lipid peroxidation [43]. Accumulating evidence has ascribed an essential pathophysiological role for ferroptosis‐like cell death in the spinal cord within various models of neuropathic pain [12].

Notably, intraperitoneal administration of ferroptosis inhibitors has been shown to alleviates pain‐like behaviors in rat models of chronic constriction injury (CCI)‐induced neuropathic pain [10, 11]. Consistently, data from our study showed an overwhelming accumulation of Fe2+, ROS, and MDA in the spinal cord of SNI rats. Meanwhile, we also observed decreased activity of GSH and SOD, as well as a decrease in protein levels of SLC7A11 and GPX4 in the spinal cord following SNI. These data support the essential role of ferroptosis in the development of neuropathic pain, suggesting that ferroptosis as a viable novel therapeutic target for neuropathic pain treatment.

Vitamin D is currently appealing growing attention across disciplines because of its diverse biological features, encompassing anti‐inflammatory, antioxidative, and neuroprotective effects [21, 44]. The biological functions of vitamin D are achieved by VitD3 through binding with the VDR, a nuclear receptor that is widely expressed in the brain and spinal cord [34]. In the present study, we demonstrated that intrathecal administration of calcitriol (1 μg, or 2 μg) had an analgesic effect in rats with neuropathic pain in a dosage‐dependent manner.

Moreover, the protein levels of VDR were found decreased in the spinal cord following SNI, which could be reversed by calcitriol treatment. Our results also indicated that VDR was specifically localized in the spinal dorsal horn neurons of SNI rats. Recently, vitamin D/VDR signaling has been reported to regulate ferroptosis by modulating signal transduction in a cell‐specific manner. For example, Hu et al. showed that VDR activation by paricalcitol attenuated cisplatin‐induced renal injury by inhibiting ferroptosis via trans‐regulation of GPX4 [45].

Similarly, Xu et al. reported that VitD3 reduced osteoblast ferroptosis by activating the nuclear factor erythroid 2: related factor 2 (NRF2)/GPX4 signaling pathway through a mechanism mediated by VDR [46]. Consistently, our study demonstrated that treatment with calcitriol effectively alleviated SNI‐induced ferroptosis in the spinal cord.

It is generally acknowledged that the GABAergic system participates in the transmission of nociceptive information in the spinal cord. Of note, GABAergic interneurons exhibit a high metabolic requirement, rendering them more vulnerable to redox dysregulation and oxidative stress [47]. Spinal GABAergic interneurons compromised by ferroptosis have been reported in a mouse model of bone cancer pain showing that ferroptosis inhibition prevented the loss of spinal GAD65+ interneurons [6]. Herein, we found that SNI‐induced downregulation of GAD65 in the spinal cord was rescued by calcitriol treatment, suggesting that VitD3 alleviates neuropathic pain by protecting spinal GABAergic interneurons from ferroptotic cell death.

To further validating the role of ferroptosis in GABAergic interneurons loss, we employed the ferroptosis agonist RSL3 to assess whether it could reverse the protective effects of calcitriol in SNI rats. Intriguingly, the improved GAD65 and antinociceptive effect induced by calcitriol were abolished by RSL3, which triggers ferroptosis by inhibition of GPX4 enzyme's function. Cumulatively, these observations indicate that the analgesic effect of VitD3 might be related to its protective effects on GABAergic interneurons by inhibiting ferroptosis.

Mitochondria play a crucial and proactive role in ferroptotic cell death through its oxidative metabolism function [14]. Excessive intracellular ROS can damage mitochondrial function by intruding mitochondrial DNA and ETC complexes, and therefore promoting ferroptosis [48]. Mounting evidence suggests that vitamin D/VDR is crucial for mitochondrial respiration and oxidative capacity, thus involved in essential bioenergetic metabolic pathways [49, 50]. Loss of VDR function has been shown to decrease mitochondrial respiration and ATP production from oxidative phosphorylation [50].

Additionally, it has been found that vitamin D supplementation improved mitochondrial biogenesis in skeletal muscle by increasing the activity and protein expression of mitochondrial ETC complexes through a nuclear mechanism by VDR [51]. In this regard, we explored the functional and morphological relevance of mitochondria in ferroptosis after VitD3 treatment. Experiments from the current study observed decreased levels of ETC Complex III‐V and ATP production, as well as aberrant mitochondrial morphology in the spinal cord of SNI rats.

Importantly, calcitriol treatment attenuated these damages. These results indicate that the anti‐ferroptosis of VitD3 is closely associated with its regulation of mitochondrial function.

Although the precise molecular mechanisms governing mitochondria‐associated ferroptosis by VitD3 in neuropathic pain are not fully understood, NOX4, a key dominator of ROS production, has been shown to promote ferroptosis through the impairment of mitochondrial oxidative metabolism [37]. The Nrf2/heme oxygenase‐1 (HO‐1) signaling pathway plays a critical role in GPX4‐dependent ferroptosis and mitochondrial dysfunction [52, 53]. Activation of Nrf2 has been demonstrated to inhibit ferroptosis and alleviate pain behaviors induced by SNI [54].

Park et al. reported that NOX4‐derived ROS can suppress Nrf2‐HO‐1 signaling pathway, thereby promoting ferroptosis in astrocytes [37]. Additionally, NOX4 can be activated through phosphorylation by PKCα [19]. PKCα has been shown to modulate mitochondrial proteins associated with respiratory processes [55]. Recent researches indicate that inactivation of PKCα and NOX4 can mitigate erastin‐induced ferroptosis [20, 56]. Here, we found that the protein expression of p‐PKCα, PKCα, and NOX4 was remarkably increased in the spinal cord after SNI.

Double immunofluorescence results showed that the p‐PKCα and NOX4 were both colocalized mostly with neurons in the spinal dorsal horn of SNI rats. More importantly, the fact that pharmacological inhibition of PKCα significantly decreased spinal NOX4 expression, attenuated ferroptosis and mitochondria dysfunction in the spinal cord, as well as mechanical allodynia resulting from SNI. Surprisingly, our data clearly showed that calcitriol treatment significantly inhibited the expression of p‐ PKCα, PKCα, and NOX4 in the spinal cord of SNI rats. Based on the above findings, it is reasonable to hypothesize that PKCα/NOX4 signaling pathway represents a potential molecular target for VitD3.

Accordingly, we found that activation of PKCα/NOX4 signaling by PKCα agonist in naïve rats induced nociceptive hypersensitivity, triggered increased ferroptosis, and led to a reduction of GAD65 and mitochondrial function in the spinal cord, all of which could be alleviated by calcitriol treatment. Although the mechanisms by which VitD3 regulated PKCα/NOX4 signaling pathway remain to be established, our present study indicates that VitD3 ameliorates neuropathic pain via preventing the loss of GABAergic interneurons in the spinal cord, at least partly by inhibiting mitochondria‐associated ferroptosis mediated by PKCα/NOX4 signaling pathway (Figure 9).

FIGURE 9

Schematic diagram of the analgesic mechanism of vitamin D3 in neuropathic pain.

Figure image at the original source: open the original paper. This file is not included in this text import.

Nevertheless, there is a limitation to our study. We exclusively used male rats, without considering sex differences. It is widely recognized that sex differences in pain and analgesia are robust, affected by genetic, epigenetic, hormonal, and environmental factors. Sex hormones, estrogen in particular, appear to promote mitochondrial biogenesis and ROS scavenging through estrogen receptors [57]. Moreover, estrogen has been demonstrated to enhance the immunomodulatory function of vitamin D by favoring its accumulation and increasing VDR expression, resulting in a more potent anti‐inflammatory response in females than in males [58].

In this respect, future studies should be carried out to determine whether VitD3‐based therapeutic strategies are more effective in females than in males, paving the way for a more personalized therapeutic approach for neuropathic pain management.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

3.1

SNI Induces Mechanical Allodynia and Ferroptosis in the Spinal Cord

In this study, we adopt SNI rats as an animal model to investigate neuropathic pain, with a focus on mechanical allodynia. The timeline of the surgery and behavior tests is depicted in Figure 1A. There is no significant difference at baseline between the sham and SNI groups regarding the ipsilateral PWT. In contrast to the sham control, SNI rats exhibited a significant reduction in PWT from Day 3 to Day 14 after SNI (Figure 1B), indicating that the SNI surgery successfully evoked significant mechanical hypersensitivity.

FIGURE 1

SNI‐induced mechanical allodynia and ferroptosis in the spinal cord. (A) The schematic timeline of the experimental procedure. (B) Mechanical allodynia evaluated by PWT at baseline and 3, 7, and 14 days after sham or SNI (n = 6 per group). ****p < 0.0001 versus sham group. (C) Time course of Fe2+, ROS, MDA, GSH, and SOD levels in the spinal cord of SNI rats (n = 5 per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus sham group. (D) Representative pictures of Perl's staining in spinal cord were shown (n = 4 per group). (E, F) Time course of ferroptosis‐related proteins SLC7A11 and GPX4 in the spinal cord after SNI (n = 6 per group). β‐Actin was used as an internal control, **p < 0.01, ****p < 0.0001 versus sham group.

Figure image at the original source: open the original paper. This file is not included in this text import.

To determine the potential involvement of ferroptosis in the development of SNI‐induced neuropathic pain, we first examined the time‐course expression of the biochemical hallmarks of ferroptosis in the spinal cord on Days 3, 7, and 14 after SNI. As shown in Figure 1C, the spinal levels of Fe2+, ROS, and MDA increased on Day 3 after SNI and continued to rise over time. Conversely, the activity of GSH and SOD, the main component of the antioxidant defense system in ferroptosis [33], persistently decreased in the spinal cord of SNI rats compared with the sham control.

Perl's staining revealed significant iron deposition that was represented as blue spots in the ipsilateral spinal dorsal horn of SNI rats, when compared to the sham control (Figure 1D). We also observed the dynamic changes of key regulator of ferroptosis, such as SLC7A11 and GPX4, both of which significantly decreased in the spinal cord of SNI rats (Figure 1E,F). These results consistently suggest that ferroptosis is involved in the development of neuropathic pain at the spinal cord level.

3.2

The Analgesic Effect of VitD3 in SNI Rats

To explore whether VitD3 could alleviate mechanical allodynia induced by SNI, calcitriol was intrathecally injected into sham and SNI rats. The timeline of this experiment is shown in Figure 2A. Firstly, a different selected dose of calcitriol (0.5, 1, or 2 μg) was given on Day 7 post‐surgery. The von Fery test was performed before calcitriol injection and at 1, 2, 4, and 6 h after the first injection. As illustrated in Figure 2B, calcitriol treatment significantly increased the ipsilateral PWT in SNI rats at an effective dose of 1 or 2 μg compared with the SNI + Vehicle group.

The effect peaked at 2 h after administration and persisted for at least 4 h. However, a low dose of calcitriol (0.5 μg) was devoid of any activity. Then, to determine whether repeated treatment with calcitriol has cumulative analgesic effects, calcitriol (1 μg) was administrated once daily for 5 consecutive days starting from Day 7 (Figure 2C). The behavioral test was conducted before and 2 h after calcitriol injection. As shown in Figure 2D, repeated calcitriol injection significantly reversed the established mechanical allodynia in SNI rats without tolerance.

These results indicate that VitD3 effectively ameliorates neuropathic pain in a dose‐dependent manner.

FIGURE 2

Analgesic effect of VitD3 on mechanical allodynia in SNI rats. (A, B) A single dose of calcitriol (0.5, 1 and 2 μg, i.t.) or vehicle was administrated on Day 7 following SNI. Mechanical allodynia was measured before injection and 1, 2, 4, and 6 h after injection (n = 6 per group). ***p < 0.001, ****p < 0.0001 versus SNI + Vehicle group. (C, D) Calcitriol (1 μg, i.t.) was given once daily from Day 7 to Day 11 following SNI.

Mechanical allodynia was conducted at 2 h after calcitriol injection from Day 7 to Day 11 following SNI (n = 6 per group). ***p < 0.001, ****p < 0.0001 versus Sham + Vehicle group, #### p < 0.0001 versus SNI + Vehicle group. (E) Time course of VDR in the spinal cord after SNI (n = 6 per group). *p < 0.05, ****p < 0.0001 versus sham group. (F) Representative blots and quantification of VDR in the spinal cord of different groups were presented (n = 6 per group). ***p < 0.001 versus Sham + Vehicle group, ## p < 0.01 versus SNI + Vehicle group. (G) Double immunofluorescence of VDR (red) and GFAP (green), IBA1 (green), and NeuN (green) in the spinal cord of SNI rats (n = 4 per group).

The white boxes indicated typical co‐staining cells. Scale bar: 100 and 50 μm.

Figure image at the original source: open the original paper. This file is not included in this text import.

VitD3 exerts its biological functions through ligand activation of VDR, which is widely expressed in the peripheral and central neurons involved in pain‐sensing and processing [34]. Therefore, we examined the effect of calcitriol on VDR expression in the spinal cord of SNI rats. As shown in Figure 2E,F, western blot results displayed decreased levels of VDR caused by SNI, partially reversed by repeated treatment with calcitriol. Then, to identify the cell type expressing VDR in the spinal dorsal horn, we examined the colocalization of VDR with the markers specific for astrocytes (GFAP), microglial (IBA‐1), and neurons (NeuN) by double immunofluorescence staining.

The results revealed that VDR predominantly colocalized with NeuN in the spinal dorsal horn, and hardly showed any overlap staining with either GFAP or Iba‐1 (Figure 2G). These findings suggest that VDR in spinal dorsal neurons may play a role in the analgesic effects of VitD3.

3.3

VitD3 Attenuates Ferroptosis and GABAergic Interneuron Loss in the Spinal Cord of SNI Rats

To investigate whether VitD3 could inhibit the enhanced ferroptosis induced by SNI, we assessed the changes in ferroptosis‐related indicators in the spinal cord. As illustrated in Figure 3A, treatment with calcitriol significantly alleviated the increased level of Fe2+, ROS, and MDA in the spinal cord compared with the SNI + Vehicle group. Meanwhile, the suppressed activity of GSH and SOD was reversed by calcitriol treatment. Furthermore, western blot analysis revealed that calcitriol treatment significantly hindered the SNI‐induced downregulation of GPX4 and SLC7A11 (Figure 3B,C).

These data support the resistant role of VitD3 in ferroptosis under neuropathic pain conditions.

FIGURE 3

VitD3 attenuated ferroptosis and GABAergic interneuron loss in the spinal cord of SNI rats. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord were measured with corresponding kits (n = 5 to 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001 versus Sham + Vehicle group, # p < 0.05, ## p < 0.01 versus SNI + Vehicle group. (B, C) Representative blots and quantification of SLC7A11 and GPX4 in the spinal cord of different groups were presented (n = 6 per group). ****p < 0.0001 versus the Sham + Vehicle group, ### p < 0.001, #### p < 0.0001 versus the SNI + Vehicle group. (D, E) Representative blots and quantification of GAD65 in the spinal cord of different groups were presented (n = 6 per group). ****p < 0.0001 versus the Sham + Vehicle group, #### p < 0.0001 versus the SNI + Vehicle group. (F) The timeline of experimental procedures. (G) Rats were intrathecally administered with calcitriol (1 μg) alone or co‐application with RSL3 (5 μg) once daily from Day 7 to Day 11 following SNI.

Mechanical allodynia was conducted at 2 h after daily treatment, **p < 0.01, ***p < 0.001 versus SNI + Calcitriol group, n = 6 per group. (H, I) Representative western blot bands and quantification of GAD65 and GPX4 in the spinal cord of SNI + Calcitriol and SNI + Calcitriol+RSL3 group were presented. ****p < 0.0001 < 0.0001 versus SNI + Calcitriol group, n = 6 per group.

Figure image at the original source: open the original paper. This file is not included in this text import.

Considering the neuroprotective effect of VitD3 in neurodegenerative disease [22], we investigated whether VitD3 could reduce SNI‐induced neuronal injury, particularly the GABAergic interneurons in the spinal cord. Glutamic acid decarboxylase 65 (GAD65) is a GABA‐synthesizing enzyme that can be used to indicate the number and functional changes of GABA interneurons [35]. Consequently, we observed a statistically significant decrease in the protein levels of GAD65 in the spinal cord following SNI, and treatment with calcitriol markedly enhanced the expression of GAD65 (Figure 3D,E).

To deeply explore whether the protective effect on GABA neurons was attributed to the inhibition of ferroptosis by calcitriol, the ferroptosis inducer RSL3 (5 μg) combined with calcitriol was intrathecally injected into SNI rats and then measured the pain behavior. The timeline of this test is displayed in Figure 3F. As shown in Figure 3G, the behavioral test showed that the RSL3 treatment partially abolished the antinociceptive effect of calcitriol. Moreover, western blot results revealed that administration of RSL3 significantly hindered the upregulation of GAD65 and GPX4 induced by calcitriol treatment (Figure 3H,I).

These data hint that VitD3 protects the spinal GABAergic interneuron against ferroptosis, thereby attenuating neuropathic pain.

3.4

VitD3 Mitigates SNI‐Induced Mitochondrial Dysfunction in the Spinal Cord

Mitochondrial metabolism dysfunction participates in governing ferroptosis and is implicated in the pathogenesis of neuropathic pain [36, 37]. Here, we evaluated the effect of VitD3 on the activity of mitochondrial oxidative metabolism in the spinal cord. Initially, we measured the ATP content in the spinal cord of sham and SNI rats. We observed that the levels of ATP were time‐dependently declined from Day 3 to Day 14 following SNI, a phenomenon that was reversed by calcitriol treatment (Figure 4A,B).

In the mitochondrial metabolic pathway, the mitochondrial ETC consists of five protein complexes and plays a pivotal role in ATP production. Subsequently, we analyzed the protein levels of the five mitochondrial ETC complex subunits. As shown in Figure 4C: H, western blot results showed that calcitriol treatment significantly restored the SNI‐induced downregulation of ETC Complex III, IV, and V (UQCRC2, MTCO1, and ATP5F1A), as compared to the SNI + Vehicle group. However, the protein levels of Complex I and II (NDUFB8 and SDHB) unexpectedly didn't meet statistical differences.

Furthermore, the mitochondrial ultrastructure in spinal neurons by using TEM exhibited swollen mitochondria, cristae rupture, and greater membrane density in response to SNI, which were reversed by calcitriol treatment (Figure 4I). These findings indicate that VitD3 could regulate the biological activities of mitochondria in the spinal cord.

FIGURE 4

VitD3 mitigated SNI‐induced mitochondrial dysfunction in the spinal cord. (A, B) The content of ATP in the spinal cord was measured. (C: H) Representative western blot bands of mitochondrial ETC complexes (NDUFB8, SDHB, UQCRC2, MTCO1, and ATP5F1A) in the spinal cord of different groups were presented. Quantitative analysis of scanning densitometry was performed. *p < 0.05, **p < 0.01 versus Sham + Vehicle group, #### p < 0.0001 versus SNI + Vehicle group, n = 4 to 6 in each group. (I) Representative electron morphological changes in the mitochondrial in the spinal cord among groups.

The labeled yellow boxes highlight the mitochondrial ultrastructure. scale bar: 1 μm and 500 nm, n = 3 in each group.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.5

PKCα/NOX4 Signaling Pathway Is Involved in the Development of SNI‐Induced Neuropathic Pain

It was previously reported that PKCα contributed to pain hypersensitivity in chronic inflammatory pain [38]. Moreover, NOX4 is a downstream effector of PKCα that generates ROS and is also involved in pain processing [39]. Accordingly, we examined the levels of p‐PKCα, PKCα, and NOX4 in the spinal cord by western blot. As illustrated in Figure 5A,B, compared with the sham control, the protein expression of p‐PKCα, PKCα, and NOX4 consistently increased in the spinal cord from Day 3 to Day 14, peaking on Day 7.

Additionally, double immunostaining showed that both p‐PKCα and NOX4 were predominately colocalized with neurons in the spinal dorsal horn, but rarely with astrocytes or microglia (Figure 5C,D). These results suggest that the PKCα/NOX4 signaling pathway may function in spinal dorsal neurons in pain processing.

FIGURE 5

PKCα/NOX4 signaling pathway was involved in the development of SNI‐induced neuropathic pain. (A, B) Time course of p‐PKCα, PKCα, and NOX4 in the spinal cord of after SNI (n = 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus sham group. (C, D) Double immunofluorescence of p‐PKCα and NOX4 with GFAP, IBA1, and NeuN in the spinal dorsal horn of SNI rats (n = 4 per group).

The white boxes indicated typical co‐staining cells. Scale bar: 100 and 50 μm. (E) The time schedule of the present experiment. (F) BIM‐1 (100 μM, i.t.) was given once daily from Day 7 to Day 11 following SNI. Mechanical allodynia was performed at 1.5 h after daily treatment. ***p < 0.001, ****p < 0.0001 versus Sham + Vehicle group, #### p < 0.000 versus SNI + Vehicle group. (G, H) Representative western blot bands and quantification of J p‐PKCα, PKCα, and NOX4 in the spinal cord among groups, **p < 0.01, ***p < 0.001 versus the sham group, ### p < 0.001, #### p < 0.0001 versus the SNI + Vehicle group, n = 6 in each group.

Figure image at the original source: open the original paper. This file is not included in this text import.

To confirm the role of the PKCα/NOX4 signaling pathway in SNI‐induced neuropathic pain, we applied a pharmacological approach using the broad‐range PKCα inhibitor BIM‐1. The timeline of this test is depicted in Figure 5E. BIM‐1(100 μM) was intrathecally injected for 5 consecutive days starting from Day 7 after SNI, and the behavioral test was conducted before and 1.5 h after BIM‐1 injection. As illustrated in Figure 5F, the behavioral test showed that the PWT was significantly increased in BIM‐1‐treated rats compared with the vehicle‐treated rats.

Importantly, administration of BIM‐1 markedly reduced the protein expression of p‐PKCα, PKCα, and NOX4 in the spinal cord (Figure 5G,H). These results suggest that the spinal PKCα/NOX4 signaling pathway plays a functional role in neuropathic pain.

3.6

Pharmacological Inhibition of PKCα/NOX4 Signaling Pathway Suppressed Ferroptosis and Mitochondrial Dysfunction

Next, to test whether the PKCα/NOX4 signaling pathway contributed to SNI‐induced ferroptosis and mitochondrial dysfunction, we assessed the changes in ferroptosis‐related indexes in the spinal cord after intrathecal injection with BIM‐1. As shown in Figure 6A, compared with the vehicle‐treated group, the level of Fe2+, ROS, and MDA were significantly decreased by BIM‐1 treatment, while the activity of GSH and SOD were increased. In response to BIM‐1 treatment, higher levels of GPX4 and SLC7A11 in the spinal cord were observed in SNI rats (Figure 6B,C).

Simultaneously, BIM‐1 treatment significantly attenuated SNI‐caused decline in ATP contents (Figure 6D). As expected, western blot results showed that BIM‐1 administration significantly increased the levels of ETC Complex III, IV, and V in the spinal cord of SNI rats, as compared to the vehicle‐treated group (Figure 6E,F). The influence of BIM‐1 on mitochondrial morphology was also evaluated, and the mitochondrial morphological injury in spinal neurons caused by SNI was alleviated by BIM‐1 treatment (Figure 6G). These results suggest that SNI‐triggered ferroptosis and mitochondrial dysfunction in the spinal cord probably in a PKCα/NOX4 signaling pathway‐dependent manner.

FIGURE 6

Pharmacological inhibition of PKCα/NOX4 signaling pathway suppressed ferroptosis and mitochondrial dysfunction. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord of SNI + Vehicle and SNI + BIM‐1 groups were measured (n = 5 to 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001 versus SNI + Vehicle group. (B, C) Representative blots and quantification of SLC7A11 and GPX4 in the spinal cord of different groups were presented (n = 5 to 6 per group). ***p < 0.001, ****p < 0.0001 versus sham group, ## p < 0.01, ### p < 0.00 versus SNI + Vehicle group. (D) The levels of ATP in spinal cord of SNI + Vehicle and SNI + BIM‐1 groups were measured (n = 6 per group). *p < 0.05 versus SNI + Vehicle group. (E, F) Representative western blot bands of mitochondrial ETC Complex III‐V (UQCRC2, MTCO1, and ATP5F1A) in the spinal cord of different groups were presented.

Quantitative analysis of scanning densitometry was performed. *p < 0.05, **p < 0.01 versus Sham + Vehicle group, # p < 0.05, ## p < 0.01 versus SNI + Vehicle group, n = 5 in each group. (G) Representative electron morphological changes of the mitochondrial in the spinal cord of SNI + Vehicle and SNI + BIM‐1 groups (n = 3 per group). The labeled yellow boxes highlight the mitochondrial ultrastructure. scale bar: 1 μm and 500 nm.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.7

VitD3 Alleviates Pain Hypersensitivity via Inhibiting PKCα/NOX4 Signaling Pathway

The molecular basis for the analgesic effect of VitD3 remains to be elucidated. Based on our above findings, we further explored the role of the PKCα/NOX4 signaling pathway in VitD3‐mediated antinociception. As a result, western blot results displayed that calcitriol treatment significantly reduced the protein levels of p‐PKCα, PKCα, and NOX4 in the spinal cord, as compared to the vehicle‐treated SNI group (Figure 7A,B). To further verify the potential relationship between the PKCα/NOX4 signaling pathway and VitD3 in nociception, we treated naïve rats with the PKCα activator PMA alone or in combination with calcitriol and analyzed the changes in pain behavior.

The schedule for the drug delivery and testing is shown in Figure 7C. PMA (2.5 μg) and calcitriol were intrathecally given in a single dose, and the PWT was measured before the injection and 0.5 to 12 h after the injection. As illustrated in Figure 7D, compared with the vehicle group, rats that received a single dose of PMA exhibited a significantly decreased PWT from 1 h after injection, and lasted at least to 12 h. Moreover, calcitriol treatment attenuated the mechanical allodynia induced by PMA administration.

The analgesic effect peaked at 2 h and lasted only for 2 h. Accordingly, the spinal segments were collected at 2 h after drug administration. As expected, western blot results showed that the spinal expression of p‐PKCα/PKCα and NOX4 was significantly enhanced in response to PMA injection, which were markedly inhibited by calcitriol treatment (Figure 7E,F). Taken together, these results highlight the involvement of PKCα/NOX4 signaling pathway in the antinociceptive effect of VitD3.

FIGURE 7

VitD3 alleviated pain hypersensitivity via inhibiting PKCα/NOX4 signaling pathway. (A, B) Representative western blot bands and quantification of p‐PKCα, PKCα, and NOX4 in the spinal cords of animals from different groups were presented. **p < 0.01 versus Sham + Vehicle group, ## p < 0.01, ### p < 0.001 versus SNI + Vehicle group, n = 6 in each group. (C) Time schedule of the experiment. (D) Naïve rats were intrathecally injected with a single dose of PMA (2.5 μg) alone or in combination with calcitriol (1 μg).

Mechanical allodynia was measured before injection and 0.5, 1, 2, 4, 6, and 12 h after injection. ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats, n = 6 in each group. (E, F) Representative western blot bands and quantification of p‐PKCα and NOX4 in the spinal cords of animals from different groups were presented. The phosphorylation levels of PKCα were normalized to the total protein levels. **p < 0.01, ***p < 0.001 compared with Vehicle‐treated rats, ## p < 0.01 compared with PMA‐treated rats, n = 4 to 6 in each group.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.8

VitD3 Preserves Spinal GABAergic Interneurons via Suppression of PKCα/NOX4 Signaling Pathway‐Mediated Ferroptosis and Mitochondrial Dysfunction

To ascertain whether VitD3 suppressed pain behaviors induced by PKCα/NOX4 pathway activation in naïve rats involves a similar mechanism in SNI rats, we further examined the expression of ferroptosis markers and GAD65 in the spinal cord. Surprisingly, PMA administration induced a dramatic elevation in Fe2+, ROS, and MDA, and a decline in GSH and SOD in the spinal cord, all of which were reversed by calcitriol treatment (Figure 8A). Additionally, calcitriol treatment significantly alleviated PMA‐induced downregulation of spinal SLC7A11 and GPX4, as well as GAD65 (Figure 8B: E).

Furthermore, the effects of VitD3 on PKCα/NOX4 pathway‐mediated mitochondrial function were also explored. As shown in Figure 8F, the ATP content was significantly decreased after PMA administration compared with the vehicle group. Intriguingly, calcitriol treatment significantly restored PMA‐induced downregulation of ATP. Simultaneously, the protein levels of ETC Complex III, IV, and V were obviously decreased in the spinal cord of PMA‐treated rats, which were dramatically alleviated by calcitriol treatment (Figure 8G,H). Furthermore, TEM results showed swollen mitochondria with reduction in cristae and rupture of the outer membrane in spinal cord neurons after PMA administration (Figure 8I).

However, calcitriol treatment attenuated these mitochondrial damages. These findings suggest that the protective effect of VitD3 on spinal GABAergic interneurons through the suppression of PKCα/NOX4 signaling pathway‐mediated ferroptosis and mitochondrial dysfunction.

FIGURE 8

VitD3 preserved spinal GABAergic interneurons via suppression of PKCα/NOX4 signaling pathway‐mediated ferroptosis and mitochondrial dysfunction. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord in different groups were assessed (n = 4 to 6 per group). **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, # p < 0.05, ## p < 0.01, ### p < 0.001 compared with PMA‐treated rats. (B, C) Representative western blot bands and quantification of SLC7A11 and GPX4 in the spinal cords of different groups were presented (n = 6 per group). ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats. (D, E) Representative western blot bands and quantification of GAD65 in the spinal cords of different groups were presented (n = 6 per group). ****p < 0.0001 compared with Vehicle‐treated rats, #### p < 0.0001 compared with PMA‐treated rats. (F) The levels of ATP in spinal cord were measured (n = 5 per group). ***p < 0.001 compared with Vehicle‐treated rats, # p < 0.05 compared with PMA‐treated rats. (G, H) Representative western blot bands of mitochondrial ETC Complex III‐V (UQCRC2, MTCO1, and ATP5F1A) in the spinal cord of different groups were presented. ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats, n = 5 to 6 in each group. (I) Representative morphological changes in the mitochondrial in the spinal cord (n = 3 per group).

The labeled yellow boxes highlight the mitochondrial ultrastructure. scale bar: 1 μm and 500 nm.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Conclusions

Overall, our study for the first time concludes that VitD3 ameliorates neuropathic pain by preventing the loss of spinal GABAergic interneurons, which is attributed to the activation of VDR and subsequent inhibition of mitochondria‐associated ferroptosis mediated by PKCα/NOX4 signaling pathway. These findings provide a rationale based on the mechanism for the translation of VitD3 from bench to bedside as an adjunctive analgesic for the management of neuropathic pain.

Source: Conclusions
Authors’ abstract

ABSTRACT

Aims

Neuropathic pain remains a significant unmet medical challenge due to its elusive mechanisms. Recent clinical observations suggest that vitamin D (VitD) holds promise in pain relief, yet its precise mechanism of action is still unclear. This study explores the therapeutical role and potential mechanism of VitD3 in spared nerve injury (SNI)‐induced neuropathic pain rat model.

Methods

The analgesic effects and underlying mechanisms of VitD3 were evaluated in SNI and naïve rat models. Mechanical allodynia was assessed using the Von Frey test. Western blotting, immunofluorescence, biochemical assay, and transmission electron microscope (TEM) were employed to investigate the molecular and cellular effects of VitD3.

Results

Ferroptosis was observed in the spinal cord following SNI. Intrathecal administration of VitD3, the active form of VitD, activated the vitamin D receptor (VDR), suppressed ferroptosis, and alleviated mechanical nociceptive behaviors. VitD3 treatment preserved spinal GABAergic interneurons, and its neuroprotective effects were eliminated by the ferroptosis inducer RSL3. Additionally, VitD3 mitigated aberrant mitochondrial morphology and oxidative metabolism in the spinal cord. Mechanistically, VitD3 inhibited SNI‐induced activation of spinal PKCα/NOX4 signaling. Inhibition of PKCα/NOX4 signaling alleviated mechanical pain hypersensitivity, accompanied by reduced ferroptosis and mitochondrial dysfunction in SNI rats.

Conversely, activation of PKCα/NOX4 signaling in naïve rats induced hyperalgesia, ferroptosis, loss of GABAergic interneurons, and mitochondrial dysfunction in the spinal cord, all of which were reversed by VitD3 treatment.

Conclusions

Our findings provide evidence that VitD3 attenuates neuropathic pain by preserving spinal GABAergic interneurons through the suppression of mitochondria‐associated ferroptosis mediated by PKCα/NOX4 signaling, probably via VDR activation. VitD, alone or in combination with existing analgesics, presents an innovative therapeutic avenue for neuropathic pain.

Read the full paper

Abbreviations

ATP5F1A

ATP synthase F1 subunit alpha

ETC

electron transport chain

GABA

gama‐aminobutyric acid

GAD65

glutamic acid decarboxylase 65

GFAP

glial fibrillary acidic protein

GPX4

glutathione‐dependent peroxidase

GSH

glutathione

IBA1

ionized calcium‐binding adapter molecule 1

MTCO1

mitochondrially encoded cytochrome c oxidase I

NDUFB8

NADH: Ubiquinone Oxidoreductase Subunit B8

NeuN

neuronal nuclei

NOX4

NADPH oxidase 4

PKCα

protein kinase C alpha

PWT

paw withdrawal threshold

ROS

reactive oxygen species

SDHB

succinate dehydrogenase complex iron sulfur subunit B

SLC7A11

subunit solute carrier family 7 member 11

SNI

spared nerve injury

UQCRC2

ubiquinol‐cytochrome c reductase core protein 2

VDR

vitamin D receptor

VitD3

vitamin D3

1

Introduction

Neuropathic pain is a debilitating pathological pain condition resulting from lesions or disease of the somatosensory nervous system [1]. It represents a major public health burden, affecting 7%: 10% of the general population and imposing a considerable negative impact on patients' somatic function and quality of life [2]. Due to the limited understanding of the intricate mechanism underlying neuropathic pain, current pharmacological therapies are woefully inadequate in relieving pain syndromes of suffers and often accompanied by significant adverse effects [3].

Consequently, there is an urgent need to elucidate the pathophysiology of neuropathic pain, enabling the development of mechanism‐based therapeutics that maximize analgesic efficacy while minimizing side effects.

Compelling evidence have proposed an imbalance between excitatory and inhibitory signals within spinal circuits in neuropathic pain [4]. Specifically, reduction in the inhibitory neurotransmitter gama‐aminobutyric acid (GABA) and the loss of GABAergic interneurons in the spinal dorsal horn are associated with hyperalgesia and allodynia [5]. Ding et al. recently demonstrated that inhibiting ferroptosis‐like cell death can prevent the loss of spinal GABAergic interneurons and alleviate bone cancer pain [6]. Ferroptosis, a new type of regulated cell death driven by iron‐dependent lipid peroxidation, has been implicated in various pathological conditions, including neurodegenerative disease, ischemic/reperfusion injury (IR), stroke, and cancer [7, 8].

Ferroptosis is characterized by oxidative stress resulting from reactive oxygen species (ROS) accumulation, which inhibits the activity of the cystine‐glutamate antiporter (system Xc‐), leading to glutathione (GSH) depletion and inactivation of glutathione‐dependent glutathione peroxidase (GPX4), thus disrupting cellular redox homeostasis [9]. Accumulating evidence indicates the pivotal role of ferroptosis in the development of neuropathic pain, and highlighting that ferroptosis is a prospective therapeutic target [10, 11, 12].

Mitochondria are responsible for energy supply through oxidative phosphorylation via a series of electron transport chain (ETC) complexes. It is also known as the principal loci for ROS production, playing a critical role in regulating oxidative stress and cell death [13]. Ferroptosis is closely associated with irreversibly damage to the mitochondrial morphology and function, which in turn triggered ferroptosis [14]. Despite the observed destroyed mitochondrial morphology, the functional relevance of mitochondrial damage in ferroptosis under neuropathic pain states has not been investigated yet.

NADPH oxidases (nicotinamide adenine dinucleotide phosphate oxidase, NOXs), a family enzymes that generate ROS [15]. NOXs consist of seven members: NOX1: 5 and the dual oxidases Duox1 and Duox2. Specifically, NOX4 is constitutively active and has been identified in nociceptive primary afferent neurons [16]. NOX4‐derived ROS can impair mitochondrial metabolism by inhibiting mitochondrial respiration and ATP production, leading to ferroptosis of astrocytes [17]. Protein kinase C α (PKCα) is an important regulator of ion channels coupled with numerous signaling cascades, and interferes with multiple processes, such as apoptosis, autophagy, cellular differentiation, and metabolism [18].

PKCα serve as an upstream activator of NOX4 through phosphorylation, and PKCα/NOX4 signaling pathway has been shown to regulate ferroptotic signaling cascade [19, 20]. Yet, the role of PKCα/NOX4 signaling in mitochondrial function and ferroptosis in the progression of neuropathic pain has not been explored.

Vitamin D, a fat‐soluble vitamin, is essential for calcium homeostasis and bone metabolism. The bioactive form of vitamin D is vitamin D3 (VitD3, also known as calcitriol), which exhibit antioxidant and neuroprotective properties through binding with the vitamin D receptor (VDR), potentially useful against neurodegenerative disease [21, 22]. An increasing number of observational studies have linked vitamin D deficiency with multiple painful manifestations, such as diabetic neuropathy, postherpetic neuralgia (PHN), bone pain, and fibromyalgia [23, 24, 25].

Vitamin D supplementation has demonstrated clinical benefits in patients with fibromyalgia or neuropathic pain [25, 26, 27]. However, the mechanism by which vitamin D modulates pain is not well understood. In this study, we utilized spared nerve injury (SNI)‐induced rat model to investigate the potential of VitD3 in treating neuropathic pain and to elucidate the possible molecular mechanisms.

2

Materials and Methods

2.1

Animals

Adult male Sprague: Dawley rats (weighing 200 to 240 g, supplied from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China) were used in this study. Rats were randomly grouped and housed in an environment with a temperature (23 ± 2°C), relative humidity (45%: 65%), lighting (12‐h light/dark cycle). All rats must acclimate to standard conditions for at least 7 days upon arrival, with free access to food and water. Animal procedures were approved by the Ethics Committee of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology (Number: TJH‐202306019) and in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and ARRIVE Guidelines for Reporting Animal Research.

All experiments were completed in the Experimental Medicine Research Center of Tongji hospital.

2.2

Chemicals and Reagents

VitD3 (Calcitriol, cat: HY‐10002, purity > 95%) was dissolved in a solution containing 10% DMSO and 90% corn oil. RSL3 (cat: HY‐100218A), an activator of ferroptosis through inactivate GPX4, was dissolved in 10% DMSO and 90% corn oil. The PKCα inhibitor bisindolylmaleimide I (BIM‐1, cat: HY‐13867) was dissolved in 10% DMSO and 40% PEG300 and 5% Tween‐80 in sterile saline. The PKCα agonist phorbol 12‐myristate 13‐acetate (PMA, cat: HY‐18739) was dissolved in 10% DMSO and 40% PEG300 and 5% Tween‐80 in sterile saline.

The vehicles were formulated on the basis of the corresponding solvent medium. All the chemicals employed in the present study were purchased from Med Chem Express (Shanghai, China). Iron Assay Kit (cat: A039‐2‐1), malondialdehyde (MDA) Assay Kit (cat: A003‐1‐1), ROS Assay Kit (cat: E004‐1‐1), Superoxide Dismutase (SOD) Assay Kit (cat: A001‐1‐1), GSH Assay Kit (cat: A006‐2‐1), and ATP Assay Kit (cat: A095‐1‐1) were purchased from Jiancheng Biology (Nanjing, China). Perl's staining Kit was purchased from Servicebio (Wuhan, China). The antibodies used in the molecular studies were showed in Table 1.

TABLE 1

Primary and secondary antibodies for western blot and immunofluorescence.

AntibodyProviderHostCatalog numberDilution for WBDilution for IF
VDRProteintechMouse67,192‐1‐Ig1:2000
AbclonalRabbitA21941:50
p‐PKCαAffinityRabbitAF83961:10001:50
PKCαAbclonalRabbitA111071:1000
NOX4ProteintechRabbit14,347‐1‐AP1:20001:50
SLC7A11AbclonalRabbitA24131:2000
GPX4AbclonalRabbitA112431:2000
GAD65Zen‐bioMouse201,3081:1000
NDUFB8AbclonalRabbitA197321:1000
SDHBAbclonalRabbitA18091:1000
UQCRC2AbclonalRabbitA43661:2000
MTCO1AbclonalRabbitA178891:1000
ATP5A1AbclonalRabbitA112171:2000
β‐ActinAbclonalRabbitAC0381:10000
IBA‐1Gene TexMouseGTX6324261:200
NeuNAbcamMouseAb1042241:200
GFAPCSTMouse#36701:200
Anti‐rabbit IgG HRPAbclonalGoatAS0141:5000
Anti‐mouse IgG HRPAbclonalGoatAS0031:5000
Coralite488‐conjugated anti‐mouse IgGProteintechGoatSA00013‐51:200
Coralite594‐conjugated anti‐rabbit IgGProteintechMouseSA00013‐81:200

Abbreviations: ATP5A1 (also term as ATP5F1A), ATP synthase F1 subunit alpha; GAD65, glutamic acid decarboxylase 65; GFAP, glial fibrillary acidic protein; GPX4, glutathione peroxidase 4; HRP, horseradish peroxidase; IBA1, ionized calcium‐binding adapter molecule 1; MTCO1, mitochondrially encoded cytochrome c oxidase I; NDUFB8, NADH: Ubiquinone Oxidoreductase Subunit B8; NeuN, neuronal nuclei; NOX4, NADPH oxidase 4; PKCα, protein kinase C alpha; SDHB, succinate dehydrogenase complex iron sulfur subunit B; SLC7A11, subunit solute carrier family 7 member 11; UQCRC2, ubiquinol‐cytochrome c reductase core protein 2; VDR, vitamin D receptor.

2.3

Experimental Design

In the present study, all rats were randomly allocated to different groups using a computer‐generated random number table. All the experimental procedures and analyses were blindly performed by researchers unaware of the group assignments. Five main experiments were designed to investigate the analgesic mechanism of VitD3 in neuropathic pain.

2.3.1
Experiment 1

Rats were randomly assigned to the sham or SNI group. Paw withdrawal thresholds (PWTs) were measured on Days 3, 7, and 14 after surgery. Then, the L4: L6 spinal cords from the sham group and the SNI group at 3, 7, and 14 days after surgery were collected for western blot and Kit detection. We chose rats 7 days after SNI for double immunofluorescence colocalization and Perl's staining.

2.3.2
Experiment 2

To verify whether a single dose of calcitriol could attenuate mechanical allodynia, rats were randomly divided into four groups, respectively: SNI + Vehicle; SNI + 0.5 μg calcitriol; SNI + 1 μg calcitriol; SNI + 2 μg calcitriol. Vehicle and different doses of calcitriol were intrathecally (i.t.) administrated on 7 days after surgery. To assess the effect of continuous calcitriol injection on mechanical allodynia in SNI, rats were randomly divided into four groups: Sham + Vehicle; Sham + calcitriol; SNI + Vehicle; SNI + calcitriol.

Calcitriol (1 μg, i.t.) was administrated once daily for 5 consecutive days, starting on the 7th day after surgery.

2.3.3
Experiment 3

To investigate whether the ferroptosis agonist RSL3 could blocked the protective effect of calcitriol, rats were randomly divided into 2 groups:SNI + calcitriol and SNI + calcitriol + RSL3. Calcitriol alone or co‐administrated with RSL3 (5 μg) was intrathecally injected once daily for 5 consecutive days, starting on the 7th after the surgery. The dose of RSL3 was chosen on the basis of unpublished data from our laboratory.

2.3.4
Experiment 4

To investigate whether pharmacological inhibition of PKCα/NOX4 signaling pathway could attenuate mechanical allodynia, rats were randomly divided into four groups: Sham + Vehicle; Sham + BIM‐1; SNI + Vehicle; SNI + BIM‐1. BIM‐1 (100 μM) was intrathecally administrated into corresponding rats according to a previous study [28], from 7 to 11 days after surgery.

2.3.5
Experiment 5

To study the role of PKCα/NOX4 signaling pathway in the analgesic effect of calcitriol, naïve rats were randomly divided into three groups: Vehicle, Vehicle + PMA, Vehicle + PMA + Calcitriol. A single dose of PMA (2 μg) or a combination of calcitriol were intrathecally injected into naïve rats. The dose of PMA was chosen on the basis of previous studies [29].

2.4

Neuropathic Pain Model

The SNI rat model of neuropathic pain was induced as previously described [30]. Briefly, the rats were anesthetized with 2.5% isoflurane and were placed in a left decubitus position; an incision of approximately 1 cm was made at the mid‐thigh level, the left sciatic nerve and its three branches (the common peroneal, tibial, sural nerves) were carefully exposed and separated. Then, the common peroneal and tibial nerves were ligated together and transected distally, leaving the sural nerve intact.

The skin incision was sutured with 3.0 silk and disinfected. The sham‐operated animals underwent exactly the same procedure without nerve injury.

2.5

Behavioral Testing

The mechanical allodynia was evaluated by measuring the hind PWT in response to von Frey filament stimuli, as previously described [31]. In brief, rats were individually positioned in test cages with a mesh floor and habituated for 30 min before von Frey testing. The von Frey filaments ranging from 1.4 to 15 g were vertically applied in ascending order on the mid‐plantar of the hind paw, bending the filament for 3 to 5 s. A positive response was defined as quick paw withdrawal, licking, or shaking.

The lowest force required to elicit a positive response was recorded as PWTs. All behavioral tests were performed between 9:00 a.m. and 6:00 p.m. by an investigator blinded to the experimental design.

2.6

Intrathecal Catheterization and Drug Administration

For intrathecal drug administration, the intrathecal catheterization was completed at least 5 days prior to sham or SNI surgery as previously reported [32]. Rats were deeply anesthetized with isoflurane (2.5%) and implanted with PE‐10 catheters (inner diameter 0.3 mm, outer diameter 0.6 mm) into the intrathecal space at the L4‐L6 level. The correct position of the catheter was confirmed by the tail‐flick response immediately following the insertion of the catheter. After surgery, 2% lidocaine (10 μL) was delivered through the intrathecal catheter, and both hind limbs of the rats showed temporary paralysis, indicating the success of catheterization.

Animals with visible motor dysfunction were excluded from the experiment. In this study, we aimed to investigate a purely spinal mechanism. All drugs were intrathecally injected at 10 μL, followed by 10 μL saline for flushing. Detailed experimental plans for animal assignment and medication are outlined in the respective timeline diagram.

2.7

Western Blot

Under deep anesthetized, the L4‐L6 spinal cord was quickly removed and homogenized in ice‐cold RIPA lysis‐buffer containing a cocktail of protease and phosphatase inhibitors. The lysates were then centrifuged at 12,000 rpm at 4°C for 15 min, and the protein concentration of supernatants was measured using BCA method. Equal amounts of protein samples (40 μg) were separated by 10% sodium dodecyl sulfate: polyacrylamide gels electrophoresis (SDS‐PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, Billerica, MA, USA). After blocking with 5% non‐fat milk for 2 h at RT, the membranes were incubated with the primary antibodies (Table 1) overnight at 4°C.

Following washes in TBST three times, the blots were incubated with an HRP‐conjugated secondary antibody for 2 h at RT and visualized with Super Lumia ECL Plus HRP Substrate Kit (Abbkine). The bolts were scanned and quantified using the ChemiDoc XRS System (Bio‐Rad, CA, USA). The intensity of bands was normalized to the β‐Actin and expressed as fold changes over the control group. For successive antibody incubations, the primary and secondary antibodies were removed using a commercial stripping solution (Epizyme Biotech, Shanghai, China), and the membranes were re‐immunoblotted for additional molecules.

2.8

Paraffin Section Preparation

After deep anesthesia with 2.5% isoflurane, rats were intracardially perfused with ice‐cold 0.1 M PBS followed by 4% paraformaldehyde in PBS. Subsequently, the L4‐L6 spinal cord segments were harvested, fixed in 4% PFA at room temperature, dehydrated, and embedded in paraffin. Four‐micrometer thick paraffin sections were used for immunofluorescence and Perl's staining.

2.9

Double‐Labeling Immunofluorescence

After deparaffinization and hydration, the sections were microwaved in 0.01 M sodium citrate (PH 6.0) for antigen retrieval. The sections were penetrated with 0.3% TritonX‐100 for 15 min and blocked with 5% donkey serum for 1 h at RT. Then, the sections were incubated with the primary antibodies (Table 1) overnight at 4°C. After washing with PBS three times, the sections were incubated with the secondary antibodies (Table 1) for 2 h at RT. The nuclei were stained with DAPI for 5 min, and images were captured using a fluorescence microscope (BX51, OLYMPUS, Japan).

2.10

Perl's Staining and Iron Content Detection

Iron deposition was measured in spinal cord by Perl's staining. Perl's staining working solution was added to the deparaffinized and hydrated sections. Then, hemosiderin or ferric iron staining was observed under the microscope. The concentration of Fe2+ in the spinal cord expressed as nmol/g protein was measured with a kit assay according to the manufacturer's protocols.

2.11

ROS, MDA, GSH, and SOD Measurements

The contents of ROS, MAD, GSH, and SOD in spinal cord tissues were detected using commercial assay kits according to the manufacturer's protocol. The content of MDA, GSH, and SOD was expressed as nmol/g protein, μmol/g protein, and U/g protein, respectively.

2.12

Measurement of ATP Levels

The ATP levels of the spinal cord were calculated with an assay kit following the manufacturer's operation manual. The concentration of ATP was expressed in the form of μmol/g protein.

2.13

Transmission Electron Microscope

Rats were deeply anesthetized and transcardially perfused with 0.1 M PBS followed by 4% ice‐cold PFA, the spinal cord was dissected out and sliced into 1 mm2 sections. The sections were fixed in 2% glutaraldehyde, post‐fixed in 1% aqueous osmium tetraoxide for 2 h at RT, dehydrated in gradual ethanol, and embedded in epoxy resin. Ultrathin slides were obtained using ultra‐micro‐tome (Leica, Germany) and double‐stained with uranyl acetate and lead citrate. Images were captured by transmission electron microscopy (Thermo, USA).

2.14

Statistical Analysis

All experimental data are presented as mean ± SD and analyzed using GraphPad Prism version 6 (Graph Pad Software, San Diego, CA, USA). All data underwent normality testing using either the Shapiro: Wilk test. Differences in behavioral scores among groups were analyzed by two‐way repeated measures analysis of variance (ANOVA), followed by Bonferroni's post hoc test. In other trails, Student's t‐tests were used for comparisons between two groups, and one‐way ANOVA followed by the Bonferroni test was used for comparisons between multiple groups.

For all statistical analyses, p < 0.05 was interpreted as statistically significant.

3

Results

3.1

SNI Induces Mechanical Allodynia and Ferroptosis in the Spinal Cord

In this study, we adopt SNI rats as an animal model to investigate neuropathic pain, with a focus on mechanical allodynia. The timeline of the surgery and behavior tests is depicted in Figure 1A. There is no significant difference at baseline between the sham and SNI groups regarding the ipsilateral PWT. In contrast to the sham control, SNI rats exhibited a significant reduction in PWT from Day 3 to Day 14 after SNI (Figure 1B), indicating that the SNI surgery successfully evoked significant mechanical hypersensitivity.

FIGURE 1

SNI‐induced mechanical allodynia and ferroptosis in the spinal cord. (A) The schematic timeline of the experimental procedure. (B) Mechanical allodynia evaluated by PWT at baseline and 3, 7, and 14 days after sham or SNI (n = 6 per group). ****p < 0.0001 versus sham group. (C) Time course of Fe2+, ROS, MDA, GSH, and SOD levels in the spinal cord of SNI rats (n = 5 per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus sham group. (D) Representative pictures of Perl's staining in spinal cord were shown (n = 4 per group). (E, F) Time course of ferroptosis‐related proteins SLC7A11 and GPX4 in the spinal cord after SNI (n = 6 per group). β‐Actin was used as an internal control, **p < 0.01, ****p < 0.0001 versus sham group.

Figure image at the original source: open the original paper. This file is not included in this text import.

To determine the potential involvement of ferroptosis in the development of SNI‐induced neuropathic pain, we first examined the time‐course expression of the biochemical hallmarks of ferroptosis in the spinal cord on Days 3, 7, and 14 after SNI. As shown in Figure 1C, the spinal levels of Fe2+, ROS, and MDA increased on Day 3 after SNI and continued to rise over time. Conversely, the activity of GSH and SOD, the main component of the antioxidant defense system in ferroptosis [33], persistently decreased in the spinal cord of SNI rats compared with the sham control.

Perl's staining revealed significant iron deposition that was represented as blue spots in the ipsilateral spinal dorsal horn of SNI rats, when compared to the sham control (Figure 1D). We also observed the dynamic changes of key regulator of ferroptosis, such as SLC7A11 and GPX4, both of which significantly decreased in the spinal cord of SNI rats (Figure 1E,F). These results consistently suggest that ferroptosis is involved in the development of neuropathic pain at the spinal cord level.

3.2

The Analgesic Effect of VitD3 in SNI Rats

To explore whether VitD3 could alleviate mechanical allodynia induced by SNI, calcitriol was intrathecally injected into sham and SNI rats. The timeline of this experiment is shown in Figure 2A. Firstly, a different selected dose of calcitriol (0.5, 1, or 2 μg) was given on Day 7 post‐surgery. The von Fery test was performed before calcitriol injection and at 1, 2, 4, and 6 h after the first injection. As illustrated in Figure 2B, calcitriol treatment significantly increased the ipsilateral PWT in SNI rats at an effective dose of 1 or 2 μg compared with the SNI + Vehicle group.

The effect peaked at 2 h after administration and persisted for at least 4 h. However, a low dose of calcitriol (0.5 μg) was devoid of any activity. Then, to determine whether repeated treatment with calcitriol has cumulative analgesic effects, calcitriol (1 μg) was administrated once daily for 5 consecutive days starting from Day 7 (Figure 2C). The behavioral test was conducted before and 2 h after calcitriol injection. As shown in Figure 2D, repeated calcitriol injection significantly reversed the established mechanical allodynia in SNI rats without tolerance.

These results indicate that VitD3 effectively ameliorates neuropathic pain in a dose‐dependent manner.

FIGURE 2

Analgesic effect of VitD3 on mechanical allodynia in SNI rats. (A, B) A single dose of calcitriol (0.5, 1 and 2 μg, i.t.) or vehicle was administrated on Day 7 following SNI. Mechanical allodynia was measured before injection and 1, 2, 4, and 6 h after injection (n = 6 per group). ***p < 0.001, ****p < 0.0001 versus SNI + Vehicle group. (C, D) Calcitriol (1 μg, i.t.) was given once daily from Day 7 to Day 11 following SNI.

Mechanical allodynia was conducted at 2 h after calcitriol injection from Day 7 to Day 11 following SNI (n = 6 per group). ***p < 0.001, ****p < 0.0001 versus Sham + Vehicle group, #### p < 0.0001 versus SNI + Vehicle group. (E) Time course of VDR in the spinal cord after SNI (n = 6 per group). *p < 0.05, ****p < 0.0001 versus sham group. (F) Representative blots and quantification of VDR in the spinal cord of different groups were presented (n = 6 per group). ***p < 0.001 versus Sham + Vehicle group, ## p < 0.01 versus SNI + Vehicle group. (G) Double immunofluorescence of VDR (red) and GFAP (green), IBA1 (green), and NeuN (green) in the spinal cord of SNI rats (n = 4 per group).

The white boxes indicated typical co‐staining cells. Scale bar: 100 and 50 μm.

Figure image at the original source: open the original paper. This file is not included in this text import.

VitD3 exerts its biological functions through ligand activation of VDR, which is widely expressed in the peripheral and central neurons involved in pain‐sensing and processing [34]. Therefore, we examined the effect of calcitriol on VDR expression in the spinal cord of SNI rats. As shown in Figure 2E,F, western blot results displayed decreased levels of VDR caused by SNI, partially reversed by repeated treatment with calcitriol. Then, to identify the cell type expressing VDR in the spinal dorsal horn, we examined the colocalization of VDR with the markers specific for astrocytes (GFAP), microglial (IBA‐1), and neurons (NeuN) by double immunofluorescence staining.

The results revealed that VDR predominantly colocalized with NeuN in the spinal dorsal horn, and hardly showed any overlap staining with either GFAP or Iba‐1 (Figure 2G). These findings suggest that VDR in spinal dorsal neurons may play a role in the analgesic effects of VitD3.

3.3

VitD3 Attenuates Ferroptosis and GABAergic Interneuron Loss in the Spinal Cord of SNI Rats

To investigate whether VitD3 could inhibit the enhanced ferroptosis induced by SNI, we assessed the changes in ferroptosis‐related indicators in the spinal cord. As illustrated in Figure 3A, treatment with calcitriol significantly alleviated the increased level of Fe2+, ROS, and MDA in the spinal cord compared with the SNI + Vehicle group. Meanwhile, the suppressed activity of GSH and SOD was reversed by calcitriol treatment. Furthermore, western blot analysis revealed that calcitriol treatment significantly hindered the SNI‐induced downregulation of GPX4 and SLC7A11 (Figure 3B,C).

These data support the resistant role of VitD3 in ferroptosis under neuropathic pain conditions.

FIGURE 3

VitD3 attenuated ferroptosis and GABAergic interneuron loss in the spinal cord of SNI rats. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord were measured with corresponding kits (n = 5 to 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001 versus Sham + Vehicle group, # p < 0.05, ## p < 0.01 versus SNI + Vehicle group. (B, C) Representative blots and quantification of SLC7A11 and GPX4 in the spinal cord of different groups were presented (n = 6 per group). ****p < 0.0001 versus the Sham + Vehicle group, ### p < 0.001, #### p < 0.0001 versus the SNI + Vehicle group. (D, E) Representative blots and quantification of GAD65 in the spinal cord of different groups were presented (n = 6 per group). ****p < 0.0001 versus the Sham + Vehicle group, #### p < 0.0001 versus the SNI + Vehicle group. (F) The timeline of experimental procedures. (G) Rats were intrathecally administered with calcitriol (1 μg) alone or co‐application with RSL3 (5 μg) once daily from Day 7 to Day 11 following SNI.

Mechanical allodynia was conducted at 2 h after daily treatment, **p < 0.01, ***p < 0.001 versus SNI + Calcitriol group, n = 6 per group. (H, I) Representative western blot bands and quantification of GAD65 and GPX4 in the spinal cord of SNI + Calcitriol and SNI + Calcitriol+RSL3 group were presented. ****p < 0.0001 < 0.0001 versus SNI + Calcitriol group, n = 6 per group.

Figure image at the original source: open the original paper. This file is not included in this text import.

Considering the neuroprotective effect of VitD3 in neurodegenerative disease [22], we investigated whether VitD3 could reduce SNI‐induced neuronal injury, particularly the GABAergic interneurons in the spinal cord. Glutamic acid decarboxylase 65 (GAD65) is a GABA‐synthesizing enzyme that can be used to indicate the number and functional changes of GABA interneurons [35]. Consequently, we observed a statistically significant decrease in the protein levels of GAD65 in the spinal cord following SNI, and treatment with calcitriol markedly enhanced the expression of GAD65 (Figure 3D,E).

To deeply explore whether the protective effect on GABA neurons was attributed to the inhibition of ferroptosis by calcitriol, the ferroptosis inducer RSL3 (5 μg) combined with calcitriol was intrathecally injected into SNI rats and then measured the pain behavior. The timeline of this test is displayed in Figure 3F. As shown in Figure 3G, the behavioral test showed that the RSL3 treatment partially abolished the antinociceptive effect of calcitriol. Moreover, western blot results revealed that administration of RSL3 significantly hindered the upregulation of GAD65 and GPX4 induced by calcitriol treatment (Figure 3H,I).

These data hint that VitD3 protects the spinal GABAergic interneuron against ferroptosis, thereby attenuating neuropathic pain.

3.4

VitD3 Mitigates SNI‐Induced Mitochondrial Dysfunction in the Spinal Cord

Mitochondrial metabolism dysfunction participates in governing ferroptosis and is implicated in the pathogenesis of neuropathic pain [36, 37]. Here, we evaluated the effect of VitD3 on the activity of mitochondrial oxidative metabolism in the spinal cord. Initially, we measured the ATP content in the spinal cord of sham and SNI rats. We observed that the levels of ATP were time‐dependently declined from Day 3 to Day 14 following SNI, a phenomenon that was reversed by calcitriol treatment (Figure 4A,B).

In the mitochondrial metabolic pathway, the mitochondrial ETC consists of five protein complexes and plays a pivotal role in ATP production. Subsequently, we analyzed the protein levels of the five mitochondrial ETC complex subunits. As shown in Figure 4C: H, western blot results showed that calcitriol treatment significantly restored the SNI‐induced downregulation of ETC Complex III, IV, and V (UQCRC2, MTCO1, and ATP5F1A), as compared to the SNI + Vehicle group. However, the protein levels of Complex I and II (NDUFB8 and SDHB) unexpectedly didn't meet statistical differences.

Furthermore, the mitochondrial ultrastructure in spinal neurons by using TEM exhibited swollen mitochondria, cristae rupture, and greater membrane density in response to SNI, which were reversed by calcitriol treatment (Figure 4I). These findings indicate that VitD3 could regulate the biological activities of mitochondria in the spinal cord.

FIGURE 4

VitD3 mitigated SNI‐induced mitochondrial dysfunction in the spinal cord. (A, B) The content of ATP in the spinal cord was measured. (C: H) Representative western blot bands of mitochondrial ETC complexes (NDUFB8, SDHB, UQCRC2, MTCO1, and ATP5F1A) in the spinal cord of different groups were presented. Quantitative analysis of scanning densitometry was performed. *p < 0.05, **p < 0.01 versus Sham + Vehicle group, #### p < 0.0001 versus SNI + Vehicle group, n = 4 to 6 in each group. (I) Representative electron morphological changes in the mitochondrial in the spinal cord among groups.

The labeled yellow boxes highlight the mitochondrial ultrastructure. scale bar: 1 μm and 500 nm, n = 3 in each group.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.5

PKCα/NOX4 Signaling Pathway Is Involved in the Development of SNI‐Induced Neuropathic Pain

It was previously reported that PKCα contributed to pain hypersensitivity in chronic inflammatory pain [38]. Moreover, NOX4 is a downstream effector of PKCα that generates ROS and is also involved in pain processing [39]. Accordingly, we examined the levels of p‐PKCα, PKCα, and NOX4 in the spinal cord by western blot. As illustrated in Figure 5A,B, compared with the sham control, the protein expression of p‐PKCα, PKCα, and NOX4 consistently increased in the spinal cord from Day 3 to Day 14, peaking on Day 7.

Additionally, double immunostaining showed that both p‐PKCα and NOX4 were predominately colocalized with neurons in the spinal dorsal horn, but rarely with astrocytes or microglia (Figure 5C,D). These results suggest that the PKCα/NOX4 signaling pathway may function in spinal dorsal neurons in pain processing.

FIGURE 5

PKCα/NOX4 signaling pathway was involved in the development of SNI‐induced neuropathic pain. (A, B) Time course of p‐PKCα, PKCα, and NOX4 in the spinal cord of after SNI (n = 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus sham group. (C, D) Double immunofluorescence of p‐PKCα and NOX4 with GFAP, IBA1, and NeuN in the spinal dorsal horn of SNI rats (n = 4 per group).

The white boxes indicated typical co‐staining cells. Scale bar: 100 and 50 μm. (E) The time schedule of the present experiment. (F) BIM‐1 (100 μM, i.t.) was given once daily from Day 7 to Day 11 following SNI. Mechanical allodynia was performed at 1.5 h after daily treatment. ***p < 0.001, ****p < 0.0001 versus Sham + Vehicle group, #### p < 0.000 versus SNI + Vehicle group. (G, H) Representative western blot bands and quantification of J p‐PKCα, PKCα, and NOX4 in the spinal cord among groups, **p < 0.01, ***p < 0.001 versus the sham group, ### p < 0.001, #### p < 0.0001 versus the SNI + Vehicle group, n = 6 in each group.

Figure image at the original source: open the original paper. This file is not included in this text import.

To confirm the role of the PKCα/NOX4 signaling pathway in SNI‐induced neuropathic pain, we applied a pharmacological approach using the broad‐range PKCα inhibitor BIM‐1. The timeline of this test is depicted in Figure 5E. BIM‐1(100 μM) was intrathecally injected for 5 consecutive days starting from Day 7 after SNI, and the behavioral test was conducted before and 1.5 h after BIM‐1 injection. As illustrated in Figure 5F, the behavioral test showed that the PWT was significantly increased in BIM‐1‐treated rats compared with the vehicle‐treated rats.

Importantly, administration of BIM‐1 markedly reduced the protein expression of p‐PKCα, PKCα, and NOX4 in the spinal cord (Figure 5G,H). These results suggest that the spinal PKCα/NOX4 signaling pathway plays a functional role in neuropathic pain.

3.6

Pharmacological Inhibition of PKCα/NOX4 Signaling Pathway Suppressed Ferroptosis and Mitochondrial Dysfunction

Next, to test whether the PKCα/NOX4 signaling pathway contributed to SNI‐induced ferroptosis and mitochondrial dysfunction, we assessed the changes in ferroptosis‐related indexes in the spinal cord after intrathecal injection with BIM‐1. As shown in Figure 6A, compared with the vehicle‐treated group, the level of Fe2+, ROS, and MDA were significantly decreased by BIM‐1 treatment, while the activity of GSH and SOD were increased. In response to BIM‐1 treatment, higher levels of GPX4 and SLC7A11 in the spinal cord were observed in SNI rats (Figure 6B,C).

Simultaneously, BIM‐1 treatment significantly attenuated SNI‐caused decline in ATP contents (Figure 6D). As expected, western blot results showed that BIM‐1 administration significantly increased the levels of ETC Complex III, IV, and V in the spinal cord of SNI rats, as compared to the vehicle‐treated group (Figure 6E,F). The influence of BIM‐1 on mitochondrial morphology was also evaluated, and the mitochondrial morphological injury in spinal neurons caused by SNI was alleviated by BIM‐1 treatment (Figure 6G). These results suggest that SNI‐triggered ferroptosis and mitochondrial dysfunction in the spinal cord probably in a PKCα/NOX4 signaling pathway‐dependent manner.

FIGURE 6

Pharmacological inhibition of PKCα/NOX4 signaling pathway suppressed ferroptosis and mitochondrial dysfunction. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord of SNI + Vehicle and SNI + BIM‐1 groups were measured (n = 5 to 6 per group). *p < 0.05, **p < 0.01, ***p < 0.001 versus SNI + Vehicle group. (B, C) Representative blots and quantification of SLC7A11 and GPX4 in the spinal cord of different groups were presented (n = 5 to 6 per group). ***p < 0.001, ****p < 0.0001 versus sham group, ## p < 0.01, ### p < 0.00 versus SNI + Vehicle group. (D) The levels of ATP in spinal cord of SNI + Vehicle and SNI + BIM‐1 groups were measured (n = 6 per group). *p < 0.05 versus SNI + Vehicle group. (E, F) Representative western blot bands of mitochondrial ETC Complex III‐V (UQCRC2, MTCO1, and ATP5F1A) in the spinal cord of different groups were presented.

Quantitative analysis of scanning densitometry was performed. *p < 0.05, **p < 0.01 versus Sham + Vehicle group, # p < 0.05, ## p < 0.01 versus SNI + Vehicle group, n = 5 in each group. (G) Representative electron morphological changes of the mitochondrial in the spinal cord of SNI + Vehicle and SNI + BIM‐1 groups (n = 3 per group). The labeled yellow boxes highlight the mitochondrial ultrastructure. scale bar: 1 μm and 500 nm.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.7

VitD3 Alleviates Pain Hypersensitivity via Inhibiting PKCα/NOX4 Signaling Pathway

The molecular basis for the analgesic effect of VitD3 remains to be elucidated. Based on our above findings, we further explored the role of the PKCα/NOX4 signaling pathway in VitD3‐mediated antinociception. As a result, western blot results displayed that calcitriol treatment significantly reduced the protein levels of p‐PKCα, PKCα, and NOX4 in the spinal cord, as compared to the vehicle‐treated SNI group (Figure 7A,B). To further verify the potential relationship between the PKCα/NOX4 signaling pathway and VitD3 in nociception, we treated naïve rats with the PKCα activator PMA alone or in combination with calcitriol and analyzed the changes in pain behavior.

The schedule for the drug delivery and testing is shown in Figure 7C. PMA (2.5 μg) and calcitriol were intrathecally given in a single dose, and the PWT was measured before the injection and 0.5 to 12 h after the injection. As illustrated in Figure 7D, compared with the vehicle group, rats that received a single dose of PMA exhibited a significantly decreased PWT from 1 h after injection, and lasted at least to 12 h. Moreover, calcitriol treatment attenuated the mechanical allodynia induced by PMA administration.

The analgesic effect peaked at 2 h and lasted only for 2 h. Accordingly, the spinal segments were collected at 2 h after drug administration. As expected, western blot results showed that the spinal expression of p‐PKCα/PKCα and NOX4 was significantly enhanced in response to PMA injection, which were markedly inhibited by calcitriol treatment (Figure 7E,F). Taken together, these results highlight the involvement of PKCα/NOX4 signaling pathway in the antinociceptive effect of VitD3.

FIGURE 7

VitD3 alleviated pain hypersensitivity via inhibiting PKCα/NOX4 signaling pathway. (A, B) Representative western blot bands and quantification of p‐PKCα, PKCα, and NOX4 in the spinal cords of animals from different groups were presented. **p < 0.01 versus Sham + Vehicle group, ## p < 0.01, ### p < 0.001 versus SNI + Vehicle group, n = 6 in each group. (C) Time schedule of the experiment. (D) Naïve rats were intrathecally injected with a single dose of PMA (2.5 μg) alone or in combination with calcitriol (1 μg).

Mechanical allodynia was measured before injection and 0.5, 1, 2, 4, 6, and 12 h after injection. ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats, n = 6 in each group. (E, F) Representative western blot bands and quantification of p‐PKCα and NOX4 in the spinal cords of animals from different groups were presented. The phosphorylation levels of PKCα were normalized to the total protein levels. **p < 0.01, ***p < 0.001 compared with Vehicle‐treated rats, ## p < 0.01 compared with PMA‐treated rats, n = 4 to 6 in each group.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.8

VitD3 Preserves Spinal GABAergic Interneurons via Suppression of PKCα/NOX4 Signaling Pathway‐Mediated Ferroptosis and Mitochondrial Dysfunction

To ascertain whether VitD3 suppressed pain behaviors induced by PKCα/NOX4 pathway activation in naïve rats involves a similar mechanism in SNI rats, we further examined the expression of ferroptosis markers and GAD65 in the spinal cord. Surprisingly, PMA administration induced a dramatic elevation in Fe2+, ROS, and MDA, and a decline in GSH and SOD in the spinal cord, all of which were reversed by calcitriol treatment (Figure 8A). Additionally, calcitriol treatment significantly alleviated PMA‐induced downregulation of spinal SLC7A11 and GPX4, as well as GAD65 (Figure 8B: E).

Furthermore, the effects of VitD3 on PKCα/NOX4 pathway‐mediated mitochondrial function were also explored. As shown in Figure 8F, the ATP content was significantly decreased after PMA administration compared with the vehicle group. Intriguingly, calcitriol treatment significantly restored PMA‐induced downregulation of ATP. Simultaneously, the protein levels of ETC Complex III, IV, and V were obviously decreased in the spinal cord of PMA‐treated rats, which were dramatically alleviated by calcitriol treatment (Figure 8G,H). Furthermore, TEM results showed swollen mitochondria with reduction in cristae and rupture of the outer membrane in spinal cord neurons after PMA administration (Figure 8I).

However, calcitriol treatment attenuated these mitochondrial damages. These findings suggest that the protective effect of VitD3 on spinal GABAergic interneurons through the suppression of PKCα/NOX4 signaling pathway‐mediated ferroptosis and mitochondrial dysfunction.

FIGURE 8

VitD3 preserved spinal GABAergic interneurons via suppression of PKCα/NOX4 signaling pathway‐mediated ferroptosis and mitochondrial dysfunction. (A) The levels of Fe2+, ROS, MDA, GSH, and SOD in the spinal cord in different groups were assessed (n = 4 to 6 per group). **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, # p < 0.05, ## p < 0.01, ### p < 0.001 compared with PMA‐treated rats. (B, C) Representative western blot bands and quantification of SLC7A11 and GPX4 in the spinal cords of different groups were presented (n = 6 per group). ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats. (D, E) Representative western blot bands and quantification of GAD65 in the spinal cords of different groups were presented (n = 6 per group). ****p < 0.0001 compared with Vehicle‐treated rats, #### p < 0.0001 compared with PMA‐treated rats. (F) The levels of ATP in spinal cord were measured (n = 5 per group). ***p < 0.001 compared with Vehicle‐treated rats, # p < 0.05 compared with PMA‐treated rats. (G, H) Representative western blot bands of mitochondrial ETC Complex III‐V (UQCRC2, MTCO1, and ATP5F1A) in the spinal cord of different groups were presented. ***p < 0.001, ****p < 0.0001 compared with Vehicle‐treated rats, ## p < 0.01, #### p < 0.0001 compared with PMA‐treated rats, n = 5 to 6 in each group. (I) Representative morphological changes in the mitochondrial in the spinal cord (n = 3 per group).

The labeled yellow boxes highlight the mitochondrial ultrastructure. scale bar: 1 μm and 500 nm.

Figure image at the original source: open the original paper. This file is not included in this text import.
4

Discussion

Albeit the understanding of the mechanism underlying neuropathic pain has been deepened over the past decades, the first‐line pharmaceutical therapy for neuropathic pain often has limited efficacy and non‐negligible side effects [3]. Interest in Vitamin D as an alternative therapeutic approach for neuropathic pain has recently increased dramatically [40, 41]. However, the underlying mechanism of the action remains unclear. In the present study, we showed that intrathecal administration of VitD3 alleviated mechanical allodynia by preventing the loss of GABAergic interneurons in the spinal cord.

This effect may be related, at least in part, to the inhibition of mitochondrial‐associated ferroptosis mediated by the PKCα/NOX4 signaling pathway, in a VDR‐activated manner. These results provided new theoretical evidence and a novel perspective regarding the utilization of VitD3 for treating neuropathic pain.

Ferroptosis is a unique modality of regulated cell death that distinct from apoptosis and necroptosis, characterized by lipid peroxidation initiated by iron overload and ROS generation [9]. Iron overload facilitates excessive ROS production via the Fenton reaction, which interacts with polyunsaturated fatty acids (PUFAs) of lipid membranes and induce lipid peroxidation, and eventually leads to ferroptosis‐like cell death [42]. Additionally, inactivation of GPX4 by GSH depletion promotes ROS accumulation from lipid peroxidation [43]. Accumulating evidence has ascribed an essential pathophysiological role for ferroptosis‐like cell death in the spinal cord within various models of neuropathic pain [12].

Notably, intraperitoneal administration of ferroptosis inhibitors has been shown to alleviates pain‐like behaviors in rat models of chronic constriction injury (CCI)‐induced neuropathic pain [10, 11]. Consistently, data from our study showed an overwhelming accumulation of Fe2+, ROS, and MDA in the spinal cord of SNI rats. Meanwhile, we also observed decreased activity of GSH and SOD, as well as a decrease in protein levels of SLC7A11 and GPX4 in the spinal cord following SNI. These data support the essential role of ferroptosis in the development of neuropathic pain, suggesting that ferroptosis as a viable novel therapeutic target for neuropathic pain treatment.

Vitamin D is currently appealing growing attention across disciplines because of its diverse biological features, encompassing anti‐inflammatory, antioxidative, and neuroprotective effects [21, 44]. The biological functions of vitamin D are achieved by VitD3 through binding with the VDR, a nuclear receptor that is widely expressed in the brain and spinal cord [34]. In the present study, we demonstrated that intrathecal administration of calcitriol (1 μg, or 2 μg) had an analgesic effect in rats with neuropathic pain in a dosage‐dependent manner.

Moreover, the protein levels of VDR were found decreased in the spinal cord following SNI, which could be reversed by calcitriol treatment. Our results also indicated that VDR was specifically localized in the spinal dorsal horn neurons of SNI rats. Recently, vitamin D/VDR signaling has been reported to regulate ferroptosis by modulating signal transduction in a cell‐specific manner. For example, Hu et al. showed that VDR activation by paricalcitol attenuated cisplatin‐induced renal injury by inhibiting ferroptosis via trans‐regulation of GPX4 [45].

Similarly, Xu et al. reported that VitD3 reduced osteoblast ferroptosis by activating the nuclear factor erythroid 2: related factor 2 (NRF2)/GPX4 signaling pathway through a mechanism mediated by VDR [46]. Consistently, our study demonstrated that treatment with calcitriol effectively alleviated SNI‐induced ferroptosis in the spinal cord.

It is generally acknowledged that the GABAergic system participates in the transmission of nociceptive information in the spinal cord. Of note, GABAergic interneurons exhibit a high metabolic requirement, rendering them more vulnerable to redox dysregulation and oxidative stress [47]. Spinal GABAergic interneurons compromised by ferroptosis have been reported in a mouse model of bone cancer pain showing that ferroptosis inhibition prevented the loss of spinal GAD65+ interneurons [6]. Herein, we found that SNI‐induced downregulation of GAD65 in the spinal cord was rescued by calcitriol treatment, suggesting that VitD3 alleviates neuropathic pain by protecting spinal GABAergic interneurons from ferroptotic cell death.

To further validating the role of ferroptosis in GABAergic interneurons loss, we employed the ferroptosis agonist RSL3 to assess whether it could reverse the protective effects of calcitriol in SNI rats. Intriguingly, the improved GAD65 and antinociceptive effect induced by calcitriol were abolished by RSL3, which triggers ferroptosis by inhibition of GPX4 enzyme's function. Cumulatively, these observations indicate that the analgesic effect of VitD3 might be related to its protective effects on GABAergic interneurons by inhibiting ferroptosis.

Mitochondria play a crucial and proactive role in ferroptotic cell death through its oxidative metabolism function [14]. Excessive intracellular ROS can damage mitochondrial function by intruding mitochondrial DNA and ETC complexes, and therefore promoting ferroptosis [48]. Mounting evidence suggests that vitamin D/VDR is crucial for mitochondrial respiration and oxidative capacity, thus involved in essential bioenergetic metabolic pathways [49, 50]. Loss of VDR function has been shown to decrease mitochondrial respiration and ATP production from oxidative phosphorylation [50].

Additionally, it has been found that vitamin D supplementation improved mitochondrial biogenesis in skeletal muscle by increasing the activity and protein expression of mitochondrial ETC complexes through a nuclear mechanism by VDR [51]. In this regard, we explored the functional and morphological relevance of mitochondria in ferroptosis after VitD3 treatment. Experiments from the current study observed decreased levels of ETC Complex III‐V and ATP production, as well as aberrant mitochondrial morphology in the spinal cord of SNI rats.

Importantly, calcitriol treatment attenuated these damages. These results indicate that the anti‐ferroptosis of VitD3 is closely associated with its regulation of mitochondrial function.

Although the precise molecular mechanisms governing mitochondria‐associated ferroptosis by VitD3 in neuropathic pain are not fully understood, NOX4, a key dominator of ROS production, has been shown to promote ferroptosis through the impairment of mitochondrial oxidative metabolism [37]. The Nrf2/heme oxygenase‐1 (HO‐1) signaling pathway plays a critical role in GPX4‐dependent ferroptosis and mitochondrial dysfunction [52, 53]. Activation of Nrf2 has been demonstrated to inhibit ferroptosis and alleviate pain behaviors induced by SNI [54].

Park et al. reported that NOX4‐derived ROS can suppress Nrf2‐HO‐1 signaling pathway, thereby promoting ferroptosis in astrocytes [37]. Additionally, NOX4 can be activated through phosphorylation by PKCα [19]. PKCα has been shown to modulate mitochondrial proteins associated with respiratory processes [55]. Recent researches indicate that inactivation of PKCα and NOX4 can mitigate erastin‐induced ferroptosis [20, 56]. Here, we found that the protein expression of p‐PKCα, PKCα, and NOX4 was remarkably increased in the spinal cord after SNI.

Double immunofluorescence results showed that the p‐PKCα and NOX4 were both colocalized mostly with neurons in the spinal dorsal horn of SNI rats. More importantly, the fact that pharmacological inhibition of PKCα significantly decreased spinal NOX4 expression, attenuated ferroptosis and mitochondria dysfunction in the spinal cord, as well as mechanical allodynia resulting from SNI. Surprisingly, our data clearly showed that calcitriol treatment significantly inhibited the expression of p‐ PKCα, PKCα, and NOX4 in the spinal cord of SNI rats. Based on the above findings, it is reasonable to hypothesize that PKCα/NOX4 signaling pathway represents a potential molecular target for VitD3.

Accordingly, we found that activation of PKCα/NOX4 signaling by PKCα agonist in naïve rats induced nociceptive hypersensitivity, triggered increased ferroptosis, and led to a reduction of GAD65 and mitochondrial function in the spinal cord, all of which could be alleviated by calcitriol treatment. Although the mechanisms by which VitD3 regulated PKCα/NOX4 signaling pathway remain to be established, our present study indicates that VitD3 ameliorates neuropathic pain via preventing the loss of GABAergic interneurons in the spinal cord, at least partly by inhibiting mitochondria‐associated ferroptosis mediated by PKCα/NOX4 signaling pathway (Figure 9).

FIGURE 9

Schematic diagram of the analgesic mechanism of vitamin D3 in neuropathic pain.

Figure image at the original source: open the original paper. This file is not included in this text import.

Nevertheless, there is a limitation to our study. We exclusively used male rats, without considering sex differences. It is widely recognized that sex differences in pain and analgesia are robust, affected by genetic, epigenetic, hormonal, and environmental factors. Sex hormones, estrogen in particular, appear to promote mitochondrial biogenesis and ROS scavenging through estrogen receptors [57]. Moreover, estrogen has been demonstrated to enhance the immunomodulatory function of vitamin D by favoring its accumulation and increasing VDR expression, resulting in a more potent anti‐inflammatory response in females than in males [58].

In this respect, future studies should be carried out to determine whether VitD3‐based therapeutic strategies are more effective in females than in males, paving the way for a more personalized therapeutic approach for neuropathic pain management.

5

Conclusions

Overall, our study for the first time concludes that VitD3 ameliorates neuropathic pain by preventing the loss of spinal GABAergic interneurons, which is attributed to the activation of VDR and subsequent inhibition of mitochondria‐associated ferroptosis mediated by PKCα/NOX4 signaling pathway. These findings provide a rationale based on the mechanism for the translation of VitD3 from bench to bedside as an adjunctive analgesic for the management of neuropathic pain.

Conflicts of Interest

The authors declare no conflicts of interest.

Supporting information

Data S1.

Supplement file at the original source: open the original paper. This file is not included in this text import.

Acknowledgments

We would like to thank Figdraw (www.figdraw.com) for expert assistance in the pattern drawing.

Data Availability Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

References

1 L. Colloca , T. Ludman , D. Bouhassira , et al., “Neuropathic Pain ,” Nature Reviews Disease Primers 3 (2017 ): 17002 . 10.1038/nrdp.2017.2 PMC5371025 28205574
2 I. Obara , V. Telezhkin , I. Alrashdi , and P. L. Chazot , “Histamine, Histamine Receptors, and Neuropathic Pain Relief ,” British Journal of Pharmacology 177 , no. 3 (2020 ): 580Not reported599 . 31046146 10.1111/bph.14696 PMC7012972
3 E. Cavalli , S. Mammana , F. Nicoletti , P. Bramanti , and E. Mazzon , “The Neuropathic Pain: An Overview of the Current Treatment and Future Therapeutic Approaches ,” International Journal of Immunopathology and Pharmacology 33 (2019 ): 2058738419838383. 30900486 10.1177/2058738419838383 PMC6431761
4 C. Li , Y. Lei , Y. Tian , et al., “The Etiological Contribution of GABAergic Plasticity to the Pathogenesis of Neuropathic Pain ,” Molecular Pain 15 (2019 ): 1744806919847366. 30977423 10.1177/1744806919847366 PMC6509976
5 J. G. Meisner , A. D. Marsh , and D. R. Marsh , “Loss of GABAergic Interneurons in Laminae I: III of the Spinal Cord Dorsal Horn Contributes to Reduced GABAergic Tone and Neuropathic Pain After Spinal Cord Injury ,” Journal of Neurotrauma 27 , no. 4 (2010 ): 729Not reported737 . 20059302 10.1089/neu.2009.1166
6 Z. Ding , X. Liang , J. Wang , et al., “Inhibition of Spinal Ferroptosis‐Like Cell Death Alleviates Hyperalgesia and Spontaneous Pain in a Mouse Model of Bone Cancer Pain ,” Redox Biology 62 (2023 ): 102700. 37084690 10.1016/j.redox.2023.102700 PMC10141498
7 Z. L. Wang , L. Yuan , W. Li , and J. Y. Li , “Ferroptosis in Parkinson's Disease: Glia‐Neuron Crosstalk ,” Trends in Molecular Medicine 28 , no. 4 (2022 ): 258Not reported269 . 35260343 10.1016/j.molmed.2022.02.003
8 G. Lei , L. Zhuang , and B. Gan , “Targeting Ferroptosis as a Vulnerability in Cancer ,” Nature Reviews. Cancer 22 , no. 7 (2022 ): 381Not reported396 . 35338310 10.1038/s41568-022-00459-0 PMC10243716
9 S. J. Dixon , K. M. Lemberg , M. R. Lamprecht , et al., “Ferroptosis: An Iron‐Dependent Form of Nonapoptotic Cell Death ,” Cell 149 , no. 5 (2012 ): 1060Not reported1072 . 22632970 10.1016/j.cell.2012.03.042 PMC3367386
10 H. Wang , X. Huo , C. Han , et al., “Ferroptosis Is Involved in the Development of Neuropathic Pain and Allodynia ,” Molecular and Cellular Biochemistry 476 , no. 8 (2021 ): 3149Not reported3161 . 33864570 10.1007/s11010-021-04138-w
11 Y. Guo , J. Du , C. Xiao , et al., “Inhibition of Ferroptosis‐Like Cell Death Attenuates Neuropathic Pain Reactions Induced by Peripheral Nerve Injury in Rats ,” European Journal of Pain 25 , no. 6 (2021 ): 1227Not reported1240 . 33497529 10.1002/ejp.1737
12 L. Li , L. Guo , R. Gao , et al., “Ferroptosis: A New Regulatory Mechanism in Neuropathic Pain ,” Frontiers in Aging Neuroscience 15 (2023 ): 1206851. 37810619 10.3389/fnagi.2023.1206851 PMC10556472
13 B. Gan , “Mitochondrial Regulation of Ferroptosis ,” Journal of Cell Biology 220 , no. 9 (2021 ): e202105043. 34328510 10.1083/jcb.202105043 PMC8329737
14 M. Gao , J. Yi , J. Zhu , et al., “Role of Mitochondria in Ferroptosis ,” Molecular Cell 73 , no. 2 (2019 ): 354Not reported363.e353 . 30581146 10.1016/j.molcel.2018.10.042 PMC6338496
15 K. Bedard and K.‐H. Krause , “The NOX Family of ROS‐Generating NADPH Oxidases: Physiology and Pathophysiology ,” Physiological Reviews 87 , no. 1 (2007 ): 245Not reported313 . 17237347 10.1152/physrev.00044.2005
16 W. Kallenborn‐Gerhardt , K. Schröder , D. Del Turco , et al., “NADPH Oxidase‐4 Maintains Neuropathic Pain After Peripheral Nerve Injury ,” Journal of Neuroscience 32 , no. 30 (2012 ): 10136Not reported10145 . 22836249 10.1523/JNEUROSCI.6227-11.2012 PMC6703722
17 N. Boonpraman , S. Yoon , C. Y. Kim , J. S. Moon , and S. S. Yi , “NOX4 as a Critical Effector Mediating Neuroinflammatory Cytokines, Myeloperoxidase and Osteopontin, Specifically in Astrocytes in the Hippocampus in Parkinson's Disease ,” Redox Biology 62 (2023 ): 102698. 37058998 10.1016/j.redox.2023.102698 PMC10123376
18 R. K. Singh , S. Kumar , S. Kumar , et al., “Potential Implications of Protein Kinase Cα in Pathophysiological Conditions and Therapeutic Interventions ,” Life Sciences 330 (2023 ): 121999. 37536614 10.1016/j.lfs.2023.121999
19 Y. Xun , P. Zhou , Y. Yang , et al., “Role of Nox4 in High Calcium‐Induced Renal Oxidative Stress Damage and Crystal Deposition ,” Antioxidants & Redox Signaling 36 , no. 1 to 3 (2022 ): 15Not reported38 . 34435888 10.1089/ars.2020.8159
20 R. Zhou , Y. Chen , S. Li , et al., “TRPM7 Channel Inhibition Attenuates Rheumatoid Arthritis Articular Chondrocyte Ferroptosis by Suppression of the PKCalpha‐NOX4 Axis ,” Redox Biology 55 (2022 ): 102411. 35917680 10.1016/j.redox.2022.102411 PMC9344030
21 N. J. Groves , J. J. McGrath , and T. H. Burne , “Vitamin D as a Neurosteroid Affecting the Developing and Adult Brain ,” Annual Review of Nutrition 34 (2014 ): 117Not reported141 . 10.1146/annurev-nutr-071813-105557 25033060
22 C. Fantini , C. Corinaldesi , A. Lenzi , S. Migliaccio , and C. Crescioli , “Vitamin D as a Shield Against Aging ,” International Journal of Molecular Sciences 24 , no. 5 (2023 ): 4546. 36901976 10.3390/ijms24054546 PMC10002864
23 J. Y. Chen , Y. T. Lin , L. K. Wang , et al., “Hypovitaminosis Din Postherpetic Neuralgia‐High Prevalence and Inverse Association With Pain: A Retrospective Study ,” Nutrients 11 , no. 11 (2019 ): 2787. 31731694 10.3390/nu11112787 PMC6893816
24 J. R. Zadro , D. Shirley , M. Ferreira , et al., “Is Vitamin D Supplementation Effective for Low Back Pain? A Systematic Review and Meta‐Analysis ,” Pain Physician 21 , no. 2 (2018 ): 121Not reported145 . 29565945
25 A. Sari , Z. Akdoğan Altun , C. Arifoglu Karaman , B. Bilir Kaya , and B. Durmus , “Does Vitamin D Affect Diabetic Neuropathic Pain and Balance? ,” Journal of Pain Research 13 (2020 ): 171Not reported179 . 32021406 10.2147/JPR.S203176 PMC6970609
26 M. Lombardo , A. Feraco , M. Ottaviani , et al., “The Efficacy of Vitamin D Supplementation in the Treatment of Fibromyalgia Syndrome and Chronic Musculoskeletal Pain ,” Nutrients 14 , no. 15 (2022 ): 3010. 35893864 10.3390/nu14153010 PMC9330000
27 P. Lee and R. Chen , “Vitamin D as an Analgesic for Patients With Type 2 Diabetes and Neuropathic Pain ,” Archives of Internal Medicine 168 , no. 7 (2008 ): 771Not reported772 . 18413561 10.1001/archinte.168.7.771
28 L. H. Hang , S. N. Li , X. Dan , W. W. Shu , H. Luo , and D. H. Shao , “Involvement of Spinal CCR5/PKCγ Signaling Pathway in the Maintenance of Cancer‐Induced Bone Pain ,” Neurochemical Research 42 , no. 2 (2017 ): 563Not reported571 . 27848062 10.1007/s11064-016-2108-5
29 K. An , H. Rong , H. Ni , et al., “Spinal PKC Activation: Induced Neuronal HMGB1 Translocation Contributes to Hyperalgesia in a Bone Cancer Pain Model in Rats ,” Experimental Neurology 303 (2018 ): 80Not reported94 . 29428215 10.1016/j.expneurol.2018.02.003
30 I. Decosterd and C. J. Woolf , “Spared Nerve Injury: An Animal Model of Persistent Peripheral Neuropathic Pain ,” Pain 87 , no. 2 (2000 ): 149Not reported158 . 10924808 10.1016/S0304-3959(00)00276-1
31 B. W. Liu , J. Zhang , Y. S. Hong , et al., “NGF‐Induced Nav1.7 Upregulation Contributes to Chronic Post‐Surgical Pain by Activating SGK1‐Dependent Nedd4‐2 Phosphorylation ,” Molecular Neurobiology 58 , no. 3 (2021 ): 964Not reported982 . 33063281 10.1007/s12035-020-02156-1
32 L. Q. Zhang , S. J. Gao , J. Sun , et al., “DKK3 Ameliorates Neuropathic Pain via Inhibiting ASK‐1/JNK/p‐38‐Mediated Microglia Polarization and Neuroinflammation ,” Journal of Neuroinflammation 19 , no. 1 (2022 ): 129 . 35658977 10.1186/s12974-022-02495-x PMC9164405
33 F. Kuang , J. Liu , D. Tang , and R. Kang , “Oxidative Damage and Antioxidant Defense in Ferroptosis ,” Frontiers in Cell and Development Biology 8 (2020 ): 586578. 10.3389/fcell.2020.586578 PMC7527737 33043019
34 A. M. Habib , K. Nagi , N. B. Thillaiappan , V. Sukumaran , and S. Akhtar , “Vitamin D and Its Potential Interplay With Pain Signaling Pathways ,” Frontiers in Immunology 11 (2020 ): 820 . 32547536 10.3389/fimmu.2020.00820 PMC7270292
35 A. B. Patel , R. A. de Graaf , D. L. Martin , G. Battaglioli , and K. L. Behar , “Evidence That GAD65 Mediates Increased GABA Synthesis During Intense Neuronal Activity In Vivo ,” Journal of Neurochemistry 97 , no. 2 (2006 ): 385Not reported396 . 16539672 10.1111/j.1471-4159.2006.03741.x
36 C. Q. Dai , Y. Guo , and X. Y. Chu , “Neuropathic Pain: The Dysfunction of Drp1, Mitochondria, and ROS Homeostasis ,” Neurotoxicity Research 38 , no. 3 (2020 ): 553Not reported563 . 32696439 10.1007/s12640-020-00257-2
37 M. W. Park , H. W. Cha , J. Kim , et al., “NOX4 Promotes Ferroptosis of Astrocytes by Oxidative Stress‐Induced Lipid Peroxidation via the Impairment of Mitochondrial Metabolism in Alzheimer's Diseases ,” Redox Biology 41 (2021 ): 101947. 33774476 10.1016/j.redox.2021.101947 PMC8027773
38 Q. Bai , J. Shao , J. Cao , et al., “Protein Kinase C‐α Upregulates Sodium Channel Nav1.9 in Nociceptive Dorsal Root Ganglion Neurons in an Inflammatory Arthritis Pain Model of Rat ,” Journal of Cellular Biochemistry 121 , no. 1 (2020 ): 768Not reported778 . 31385361 10.1002/jcb.29322
39 W. Kallenborn‐Gerhardt , K. Schröder , and A. Schmidtko , “NADPH Oxidases in Pain Processing ,” Antioxidants (Basel) 11 , no. 6 (2022 ): 1162. 35740059 10.3390/antiox11061162 PMC9219759
40 H. R. Banafshe , M. J. Khoshnoud , A. Abed , M. Saghazadeh , and A. Mesdaghinia , “Vitamin D Supplementation Attenuates the Behavioral Scores of Neuropathic Pain in Rats ,” Nutritional Neuroscience 22 , no. 10 (2019 ): 700Not reported705 . 29431049 10.1080/1028415X.2018.1435485
41 M. C. Q. Santos , T. Silva , F. Silva , et al., “Effects of Vitamin D Administration on Nociception and Spinal Cord Pro‐Oxidant and Antioxidant Markers in a Rat Model of Neuropathic Pain ,” Brazilian Journal of Medical and Biological Research 54 , no. 10 (2021 ): e11207. 34378677 10.1590/1414-431X2021e11207 PMC8365876
42 Y. Xie , W. Hou , X. Song , et al., “Ferroptosis: Process and Function ,” Cell Death and Differentiation 23 , no. 3 (2016 ): 369Not reported379 . 26794443 10.1038/cdd.2015.158 PMC5072448
43 W. S. Yang , R. SriRamaratnam , M. E. Welsch , et al., “Regulation of Ferroptotic Cancer Cell Death by GPX4 ,” Cell 156 , no. 1 to 2 (2014 ): 317Not reported331 . 24439385 10.1016/j.cell.2013.12.010 PMC4076414
44 J. Li , Y. Cao , J. Xu , et al., “Vitamin D Improves Cognitive Impairment and Alleviates Ferroptosis via the Nrf2 Signaling Pathway in Aging Mice ,” International Journal of Molecular Sciences 24 , no. 20 (2023 ): 15315. 37894993 10.3390/ijms242015315 PMC10607218
45 Z. Hu , H. Zhang , B. Yi , et al., “VDR Activation Attenuate Cisplatin Induced AKI by Inhibiting Ferroptosis ,” Cell Death & Disease 11 , no. 1 (2020 ): 73 . 31996668 10.1038/s41419-020-2256-z PMC6989512
46 P. Xu , B. Lin , X. Deng , K. Huang , Y. Zhang , and N. Wang , “VDR Activation Attenuates Osteoblastic Ferroptosis and Senescence by Stimulating the Nrf2/GPX4 Pathway in Age‐Related Osteoporosis ,” Free Radical Biology & Medicine 193 , no. Pt 2 (2022 ): 720Not reported735 . 36402439 10.1016/j.freeradbiomed.2022.11.013
47 J. Yowtak , J. Wang , H. Y. Kim , Y. Lu , K. Chung , and J. M. Chung , “Effect of Antioxidant Treatment on Spinal GABA Neurons in a Neuropathic Pain Model in the Mouse ,” Pain 154 , no. 11 (2013 ): 2469Not reported2476 . 23880056 10.1016/j.pain.2013.07.024 PMC3816493
48 H. P. Indo , M. Davidson , H. C. Yen , et al., “Evidence of ROS Generation by Mitochondria in Cells With Impaired Electron Transport Chain and Mitochondrial DNA Damage ,” Mitochondrion 7 , no. 1 to 2 (2007 ): 106Not reported118 . 17307400 10.1016/j.mito.2006.11.026
49 A. Matta Reddy , M. Iqbal , H. Chopra , et al., “Pivotal Role of Vitamin D in Mitochondrial Health, Cardiac Function, and Human Reproduction ,” EXCLI Journal 21 (2022 ): 967Not reported990 . 36110560 10.17179/excli2022-4935 PMC9441677
50 C. M. Latham , C. R. Brightwell , A. R. Keeble , et al., “Vitamin D Promotes Skeletal Muscle Regeneration and Mitochondrial Health ,” Frontiers in Physiology 12 (2021 ): 660498. 33935807 10.3389/fphys.2021.660498 PMC8079814
51 J. Salles , A. Chanet , C. Guillet , et al., “Vitamin D Status Modulates Mitochondrial Oxidative Capacities in Skeletal Muscle: Role in Sarcopenia ,” Communications Biology 5 , no. 1 (2022 ): 1288 . 36434267 10.1038/s42003-022-04246-3 PMC9700804
52 Z. Tang , Z. Chen , M. Guo , et al., “NRF2 Deficiency Promotes Ferroptosis of Astrocytes Mediated by Oxidative Stress in Alzheimer's Disease ,” Molecular Neurobiology 61 (2024 ): 7517Not reported7533 . 38401046 10.1007/s12035-024-04023-9
53 P. Xiao , H. Huang , H. Zhao , et al., “Edaravone Dexborneol Protects Against Cerebral Ischemia/Reperfusion‐Induced Blood‐Brain Barrier Damage by Inhibiting Ferroptosis via Activation of Nrf‐2/HO‐1/GPX4 Signaling ,” Free Radical Biology & Medicine 217 (2024 ): 116Not reported125 . 38548187 10.1016/j.freeradbiomed.2024.03.019
54 X. Zhang , T. Song , M. Zhao , et al., “Sirtuin 2 Alleviates Chronic Neuropathic Pain by Suppressing Ferroptosis in Rats ,” Frontiers in Pharmacology 13 (2022 ): 827016. 35401208 10.3389/fphar.2022.827016 PMC8984153
55 N. Kvirkvelia , M. McMenamin , M. Warren , et al., “Kidney‐Targeted Inhibition of Protein Kinase C‐α Ameliorates Nephrotoxic Nephritis With Restoration of Mitochondrial Dysfunction ,” Kidney International 94 , no. 2 (2018 ): 280Not reported291 . 29731111 10.1016/j.kint.2018.01.032 PMC6084791
56 J. Dächert , V. Ehrenfeld , K. Habermann , N. Dolgikh , and S. Fulda , “Targeting Ferroptosis in Rhabdomyosarcoma Cells ,” International Journal of Cancer 146 , no. 2 (2020 ): 510Not reported520 . 31173656 10.1002/ijc.32496
57 R. Ventura‐Clapier , J. Piquereau , V. Veksler , and A. Garnier , “Estrogens, Estrogen Receptors Effects on Cardiac and Skeletal Muscle Mitochondria ,” Frontiers in Endocrinology (Lausanne) 10 (2019 ): 557 . 10.3389/fendo.2019.00557 PMC6702264 31474941
58 M. L. Dupuis , M. T. Pagano , M. Pierdominici , and E. Ortona , “The Role of Vitamin D in Autoimmune Diseases: Could Sex Make the Difference? ,” Biology of Sex Differences 12 , no. 1 (2021 ): 12 . 33436077 10.1186/s13293-021-00358-3 PMC7802252
Publication and source details

Original title: Vitamin D3 Attenuates Neuropathic Pain via Suppression of Mitochondria‐Associated Ferroptosis by Inhibiting PKCα/NOX4 Signaling Pathway

Wencui Zhang; Shangchen Yu; Bo Jiao; Caixia Zhang; Kaiwen Zhang; Baowen Liu; Xianwei Zhang

CNS Neuroscience & Therapeutics · 2024

* Correspondence:
Baowen Liu (baowenliu@tjh.tjmu.edu.cn)
Xianwei Zhang (ourpain@163.com)
© 2024 The Author(s). CNS Neuroscience & Therapeutics published by John Wiley & Sons Ltd.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.National Natural Science Foundation of China 10.13039/5011000018092101103482

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T03:44:40.540282+00:00

DOI: 10.1111/cns.70067 · PMC11427799